[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 197
1. Ojima H, Araki K, Kato T, Okamura K, Manda R, Hirayama I, Hosouchi Y, Nishida Y, Kuwano H: Clinicopathological characteristics and outcome indicators of stage II gastric cancer according to the Japanese classification of gastric cancer. Anticancer Res; 2006 Mar-Apr;26(2B):1385-90
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics and outcome indicators of stage II gastric cancer according to the Japanese classification of gastric cancer.
  • BACKGROUND: The characteristics of stage II gastric cancer according to the Japanese Classification of Gastric Cancer (JCGC) were examined and the high-risk factors predicting poor prognosis were detected.
  • PATIENTS AND METHODS: In total, 107 patients, who underwent clinically curative gastrectomy with D2 lymphadenectomy for stage II gastric cancer, were included.
  • Survival curves of the depth of invasion, lymph node metastasis, the ratio of involved: resected lymph nodes and chemotherapy treatment were compared.
  • Survival rates with adjuvant chemotherapy were slightly higher than without adjuvant chemotherapy, but the difference was not significant.
  • CONCLUSION: pT2pN1 (stage II) gastric cancers according to the JCGC, especially pSSpN1 cases, included stage IIIB and IV gastric cancers according to the International Union Against Cancer / American Joint Committee on Cancer (UICC/AJCC); therefore, the prognosis of these might be poor.
  • With pSSpN1 cases, according to the JCGC, anticancer chemotherapy equivalent to that required for stage III gastric cancer cases is necessary.
  • [MeSH-major] Stomach Neoplasms / classification. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Gastrectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619548.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


2. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K, ACTS-GC Group: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med; 2007 Nov 1;357(18):1810-20
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
  • BACKGROUND: Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine.
  • We tested S-1 as adjuvant chemotherapy in patients with curatively resected gastric cancer.
  • METHODS: Patients in Japan with stage II or III gastric cancer who underwent gastrectomy with extended (D2) lymph-node dissection were randomly assigned to undergo surgery followed by adjuvant therapy with S-1 or to undergo surgery only.
  • The treatment regimen consisted of 6-week cycles in which, in principle, 80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks.
  • Adverse events of grade 3 or grade 4 (defined according to the Common Toxicity Criteria of the National Cancer Institute) that were relatively common in the S-1 group were anorexia (6.0%), nausea (3.7%), and diarrhea (3.1%).
  • CONCLUSIONS: S-1 is an effective adjuvant treatment for East Asian patients who have undergone a D2 dissection for locally advanced gastric cancer. (ClinicalTrials.gov number, NCT00152217 [ClinicalTrials.gov].).
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Combinations. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Metastasis / prevention & control. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Massachusetts Medical Society.
  • [CommentIn] N Engl J Med. 2007 Nov 1;357(18):1863-5 [17978296.001]
  • [CommentIn] Nat Clin Pract Oncol. 2008 Jul;5(7):370-1 [18521116.001]
  • [ErratumIn] N Engl J Med. 2008 May 1;358(18):1977
  • (PMID = 17978289.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00152217
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


3. Javle M, Hsueh CT: Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol; 2010;3:11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have reviewed the pivotal presentations related to gastrointestinal malignancies from 2009 annual meeting of the American Society of Clinical Oncology with the theme of "personalizing cancer care".
  • Adding trastuzumab to chemotherapy improved the survival of patients with advanced gastric cancer overexpressing human epidermal growth factor receptor 2.
  • Gemcitabine plus cisplatin has become a new standard for first-line treatment of advanced biliary cancer.
  • Octreotide LAR significantly lengthened median time to tumor progression compared with placebo in patients with metastatic neuroendocrine tumors of the midgut.
  • Addition of oxaliplatin to fluoropyrimidines for preoperative chemoradiotherapy in patients with stage II or III rectal cancer did not improve local tumor response but increased toxicities.
  • Bevacizumab did not provide additional benefit to chemotherapy in adjuvant chemotherapy for stage II or III colon cancer.
  • In patients with resected stage II colon cancer, recurrence score estimated by multigene RT-PCR assay has been shown to provide additional risk stratification.
  • In stage IV colorectal cancer, data have supported the routine use of prophylactic skin treatment in patients receiving antibody against epidermal growth factor receptor, and the use of upfront chemotherapy as initial management in patients with synchronous metastasis without obstruction or bleeding from the primary site.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / therapy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7 [10560850.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] J Clin Oncol. 2011 Jul 10;29(20):2773-80 [21606427.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):48-54 [19932054.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • [Cites] Gut. 2003 Apr;52(4):568-73 [12631671.001]
  • [Cites] Ann Surg Oncol. 2003 Jun;10(5):539-45 [12794020.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):35-42 [14695316.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Science. 1985 Dec 6;230(4730):1132-9 [2999974.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):249-56 [9572617.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):273-8 [15668283.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1140-6 [15894548.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1898-905 [16219623.001]
  • [Cites] Gene. 2006 Jan 17;366(1):2-16 [16377102.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Dig Dis Sci. 2006 Aug;51(8):1371-9 [16868827.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):795-805 [17031648.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6913s-20s [18006800.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] Int J Oncol. 2008 Jan;32(1):89-95 [18097546.001]
  • [Cites] Int J Colorectal Dis. 2008 Jun;23(6):559-68 [18330581.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] J Vasc Interv Radiol. 2008 Jun;19(6):855-61 [18503899.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1523-9 [18441328.001]
  • [Cites] J Hematol Oncol. 2009;2:9 [19236713.001]
  • [Cites] J Clin Oncol. 2009 Apr 10;27(11):1814-21 [19273709.001]
  • [Cites] J Clin Oncol. 2009 Jul 1;27(19):3117-25 [19451425.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3379-84 [19487380.001]
  • [Cites] Br J Cancer. 2009 Aug 18;101(4):621-7 [19672264.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4656-63 [19704057.001]
  • [Cites] World J Surg Oncol. 2009;7:80 [19886993.001]
  • [Cites] J Clin Oncol. 2010 Jan 20;28(3):466-74 [20008640.001]
  • (PMID = 20331897.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC2856525
  •  go-up   go-down


Advertisement
4. Ishido K, Azuma M, Koizumi W, Takeuchi A, Sakuramoto S, Watanabe M, Okayasu I: Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy. Pharmacogenet Genomics; 2009 Dec;19(12):955-64
Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827856970 for PMID:19898266 [PharmGKB] .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy.
  • OBJECTIVES: Many studies have reported that low intratumoral mRNA expression of thymidylate synthase (TS) is an important biomarker of response to chemotherapy in patients with unresectable advanced gastric cancer.
  • However, the role of gene expression profile of patients who received postoperative adjuvant chemotherapy remains unclear.
  • METHODS: Seventy-nine patients with stage II or III advanced gastric cancer who underwent gastrectomy were analyzed.
  • Thirty-nine patients received adjuvant chemotherapy with S-1 after surgery (S-1 group) and 40 patients underwent surgery only (surgery group).
  • Formalin-fixed, paraffin-embedded tumor tissues were dissected by the laser-captured microdissection technique and analyzed for target gene expressions using a quantitative real-time polymerase chain reaction.
  • CONCLUSION: Our results suggested that intratumoral TS expression is an independent prognostic factor in patients with gastric cancer who received postoperative adjuvant chemotherapy with S-1.
  • [MeSH-major] Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / genetics. Tegafur / therapeutic use. Thymidylate Synthase / genetics
  • [MeSH-minor] Aged. Biomarkers, Pharmacological. Drug Combinations. Female. Gastrectomy. Humans. Male. Middle Aged. Pilot Projects. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898266.001).
  • [ISSN] 1744-6880
  • [Journal-full-title] Pharmacogenetics and genomics
  • [ISO-abbreviation] Pharmacogenet. Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Pharmacological; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


5. Strauss J, Hershman DL, Buono D, McBride R, Clark-Garvey S, Woodhouse SA, Abrams JA, Neugut AI: Use of adjuvant 5-fluorouracil and radiation therapy after gastric cancer resection among the elderly and impact on survival. Int J Radiat Oncol Biol Phys; 2010 Apr;76(5):1404-12
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of adjuvant 5-fluorouracil and radiation therapy after gastric cancer resection among the elderly and impact on survival.
  • PURPOSE: In randomized trials patients with resected nonmetastatic gastric cancer who received adjuvant chemotherapy and radiotherapy (chemoRT) had better survival than those who did not.
  • We investigated the effectiveness of adjuvant chemoRT after gastric cancer resection in an elderly general population and its effects by stage.
  • METHODS AND MATERIALS: We identified individuals in the Surveillance, Epidemiology, and End Results-Medicare database aged 65 years or older with Stage IB through Stage IV (M0) gastric cancer, from 1991 to 2002, who underwent gastric resection, using multivariate modeling to analyze predictors of chemoRT use and survival.
  • RESULTS: Among 1,993 patients who received combined chemoRT or no adjuvant therapy after resection, having a later year of diagnosis, having a more advanced stage, being younger, being white, being married, and having fewer comorbidities were associated with combined treatment.
  • Among 1,476 patients aged less than 85 years who survived more than 4 months, the 313 who received combined treatment had a lower mortality rate (hazard ratio, 0.83; 95% confidence interval, 0.71-0.98) than the 1,163 who received surgery alone.
  • Adjuvant therapy significantly reduced the mortality rate for Stages III and IV (M0), trended toward improved survival for Stage II, and showed no benefit for Stage IB.
  • CONCLUSIONS: The association of combined adjuvant chemoRT with improved survival in an overall analysis of Stage IB through Stage IV (M0) resected gastric cancer is consistent with clinical trial results and suggests that, in an elderly population, adjuvant chemoradiotherapy is effective.
  • However, our observational data suggest that adjuvant treatment may not be effective for Stage IB cancer, is possibly appropriate for Stage II, and shows significant survival benefits for Stages III and IV (M0) for those aged less than 80 years.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3408-15 [9363873.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):314-9 [9010104.001]
  • [Cites] Cancer Detect Prev. 1999;23(5):428-34 [10468896.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1198-205 [10519898.001]
  • [Cites] Breast Cancer Res Treat. 2005 Sep;93(1):41-7 [16184457.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):660-9 [17582625.001]
  • [Cites] Ann Epidemiol. 2007 Aug;17(8):584-90 [17531502.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):500-7 [18026800.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1073-80 [17905529.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):921-32 [10679663.001]
  • [Cites] Ann Epidemiol. 2000 May;10(4):224-38 [10854957.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] Cancer J. 2001 May-Jun;7(3):213-8 [11419029.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Soc Sci Med. 2001 Dec;53(11):1513-24 [11710426.001]
  • [Cites] Ann Intern Med. 2002 Mar 5;136(5):349-57 [11874307.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2643-50 [12039925.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-43-8 [12187167.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-49-54 [12187168.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-55-61 [12187169.001]
  • [Cites] Med Care. 2003 Mar;41(3):442-6 [12618647.001]
  • [Cites] J Am Geriatr Soc. 1985 Sep;33(9):585-9 [4031335.001]
  • [Cites] JAMA. 1986 Jun 27;255(24):3385-90 [3712698.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] JAMA. 1987 May 22-29;257(20):2766-70 [3573271.001]
  • [Cites] J Clin Epidemiol. 1992 Jun;45(6):613-9 [1607900.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):594-601 [8319193.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):377-83 [8293403.001]
  • [Cites] Med Care. 1998 Sep;36(9):1337-48 [9749657.001]
  • (PMID = 19540074.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024156; United States / NCRR NIH HHS / RR / ULI RR024156; United States / NCI NIH HHS / CA / R25 CA094061; United States / NCI NIH HHS / CA / K07 CA132892-04; United States / NCI NIH HHS / CA / CA132892-04; United States / NCI NIH HHS / CA / CA094061; United States / NCI NIH HHS / CA / K07 CA132892
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS455659; NLM/ PMC3617616
  •  go-up   go-down


6. Kim R, Yoshida K, Toge T: Current status and future perspectives of post-operative adjuvant therapy for gastric carcinoma. Anticancer Res; 2002 Jan-Feb;22(1A):283-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status and future perspectives of post-operative adjuvant therapy for gastric carcinoma.
  • The clinical benefit of post-operative adjuvant immunochemotherapy for survival of patients with gastric carcinoma is unclear, although a number of prospective randomized controlled studies have been conducted.
  • The current status and future perspectives of post-operative adjuvant chemotherapy in gastric carcinoma have been evaluated in terms of survival benefit.
  • A meta-analysis, however, indicated a survival benefit in patients treated with post-operative adjuvant chemotherapy including mitomycin, anthracyclines, cyclophosphamide, alkylating agents and 5-fluorouracil (odds ratio: 0.8 to approximately 0.82, 95% CI<1.0).
  • The survival benefit was observed in patients with stage II and stage III gastric carcinoma, but not those with stage I.
  • Although combination therapy with mitomycin, 5-fluorouracil and non-specific immunomodulators, such as PSK and OK-432, appeared to improve overall survival without immunomodulators, the survival effect of immunomodulators is still not clear.
  • There are several possible reasons why the survival benefit of adjuvant chemotherapy or immunochemotherapy is small and marginal compared to surgery alone: (i) low efficacy of the chemotherapy regimen;.
  • (ii) small sample size; and (iii) differences in chemosensitivity of treated patients based on genetic background.
  • The determination of subgroups responsive to chemotherapy and the development of a rationale-based and molecular-targeted chemotherapy are required to clearly demonstrate whether there is a survival benefit of post-operative adjuvant chemotherapy in gastric carcinoma.
  • [MeSH-major] Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Forecasting. Humans. Immunotherapy. Randomized Controlled Trials as Topic. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12017304.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 57
  •  go-up   go-down


7. Kubota T: New chemotherapy strategies for gastric cancer. In Vivo; 2008 May-Jun;22(3):273-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New chemotherapy strategies for gastric cancer.
  • Gastric cancer chemotherapy has entered a new era with the introduction of new drugs such as S-1, irinotecan (CPT-11), paclitaxel and docetaxel.
  • Recent phase III studies have indicated that S-1 monotherapy, a remnant reference arm from a previous study, was not inferior to 5-FU alone, and that the combination of S-1 with cisplatin and CPT-11 showed higher efficacy than S-1 alone with tolerable side-effects for advanced and recurrent gastric cancer.
  • In the adjuvant setting, S-1 monotherapy prolonged survival following surgery compared with surgery alone after curative extended (D2) lymph-node dissection for stage II/III gastric cancer.
  • However, some issues remain, such as the sequence of several duplet chemotherapies, treatment following cases of S-1 failure, the relative efficacy of doublet and triplet therapies, and the impact of molecular-targeting.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials, Phase III as Topic. Humans. Recurrence

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18610735.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 16
  •  go-up   go-down


8. Tsujinaka T, Shiozaki H, Yano M, Kikkawa N, Takami M, Monden M: Prognostic factors for recurrence in stage II and III gastric cancer patients receiving a curative resection and postoperative adjuvant chemotherapy. Oncol Rep; 2001 Jan-Feb;8(1):33-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for recurrence in stage II and III gastric cancer patients receiving a curative resection and postoperative adjuvant chemotherapy.
  • Prognostic value of clinicopathologic factors and biologic markers was analyzed in 185 patients who received a curative resection and adjuvant chemotherapy of pathologically confirmed stage II or III gastric cancer.
  • No difference was found between the chemotherapeutic regimens according to the frequency of recurrence, but tumor type, histology, depth of invasion, nodal metastasis, and lymphatic and venous invasion were significantly different between recurrent (n=62) and non-recurrent (n=123) patients.
  • Multivariate analyses showed that depth of invasion, level 2 lymph node metastasis and tumor histology were risk factors for recurrence.
  • [MeSH-major] Adenocarcinoma / surgery. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. DNA, Neoplasm / analysis. Gastrectomy. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local / epidemiology. Proliferating Cell Nuclear Antigen / analysis. Stomach Neoplasms / surgery. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adult. Aged. Aneuploidy. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Immunoenzyme Techniques. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Invasiveness. Neoplasm Staging. Postoperative Period. Prognosis. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11115565.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Liang QL, Pan DC, Yin ZM, Liu GX, Yang Q, Xie JR, Cai LZ, Fu YW: [Clinical value of serum soluble Apo-1/Fas for predicting biological behaviors and prognosis of gastric carcinoma]. Ai Zheng; 2002 Feb;21(2):174-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of serum soluble Apo-1/Fas for predicting biological behaviors and prognosis of gastric carcinoma].
  • BACKGROUND & OBJECTIVE: Literatures reported that the soluble Apo-1/Fas(sApo-1/Fas) levels in serum of patients with malignant carcinoma were higher than that in normal control subject, but there were fewer studies was seldom to detect the level of sApo-1/Fas in patients with malignancy carcinoma and effect of chemotherapy; the subject is to detect the level of sApo-1/Fas in patients with gastric carcinoma and effect of chemotherapy on it, and to investigate its clinical value.
  • METHODS: Enzyme linked immunosorbent assays(ELISA) was available to detect the level of sApo-1/Fas in 42 case of patients with gastric carcinoma before and after chemotherapy, as compared with 30 case of normal control subject.
  • RESULTS: Levels of sApo-1/Fas were elevated in all subgroups of patients with gastric carcinoma as compared to the controls (P < 0.01), sApo-1/Fas was correlated with clinical stage and histological grade, and not with sex, age; the sApo-1/Fas level in stage IV was higher in comparison with stage III and II (P < 0.05-0.01), and in stage III it was higher than in stage II (P < 0.05); being lower in the well differentiated and moderately differentiated than the poorly differentiated(P < 0.05-0.01), that the sApo-1/Fas levels were remarkably reduced in complete remission or partial remission patients(P < 0.01) after chemotherapy.
  • CONCLUSION: sApo-1/Fas may play closely reflect growth and regulation in gastric carcinoma, it may be a predictor for biological behaviors and prognosis of gastric carcinoma; sApo-1/Fas may be a new target in treating gastric carcinoma.
  • [MeSH-major] Antigens, CD95 / blood. Stomach Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12479070.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD95
  •  go-up   go-down


10. Maruyama M, Nagahama Y, Sato E, Maruyama S, Sanada T, Koide A, Ohhinata R, Shima Y, Ebuchi M: [Influence of intraperitoneal chemotherapy to a recurrence pattern of gastric cancer with serosal exposure]. Gan To Kagaku Ryoho; 2007 Nov;34(12):1946-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influence of intraperitoneal chemotherapy to a recurrence pattern of gastric cancer with serosal exposure].
  • We analyzed a recurrence pattern and prognosis of 42 gastric cancer cases with histological serosal exposure of cancer and without macroscopical residual cancer in the operation.
  • These cases received adjuvant MTX-5-FU chemotherapy intraperitoneally.
  • Twenty four patients showed a recurrence of gastric cancer.
  • Seventeen patients (71%) developed peritoneal seeding, which means intraperitoneal chemotherapy made no influence to the pattern of recurrence of gastric cancer with serosal invasion.
  • All of the recurred patients with Stage II and IIIA gastric cancer and about 60% of the recurred patients with Stage IIB and IV developed peritoneal metastasis.
  • Intraperitoneal chemotherapy of MTX-5-FU did not touch the pattern of recurrence of gastric cancer with serosal invasion, but the analysis of the prognosis revealed a possibility of improvement of the prognosis.
  • [MeSH-major] Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secretion. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219860.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Migita K, Watanabe A, Sakamoto C, Nakamura T, Ohyama T, Ishikawa H, Yamamoto K: [A case of multiple bone metastases from gastric cancer treated with combination chemotherapy of S-1 and CDDP]. Gan To Kagaku Ryoho; 2007 Jun;34(6):929-31
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of multiple bone metastases from gastric cancer treated with combination chemotherapy of S-1 and CDDP].
  • We report a case of multiple bone metastases from gastric cancer treated with combination chemotherapy of S-1 and CDDP.
  • A 54-year-old man underwent distal gastrectomy for gastric cancer (Stage II) in March 2003.
  • The patient was treated with combination chemotherapy of S-1 and CDDP.
  • After one course of the treatment, DIC was resolved.
  • Although combination chemotherapy of S-1 and DOC was administered, the patient died of DIC in August 2006.
  • Combination chemotherapy of S-1 and CDDP is considered effective treatment for prolonging survival in cases of gastric cancer with bone metastases.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Gastrectomy / methods. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Oxonic Acid / administration & dosage. Postoperative Period. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565259.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Teshima S, Saito T, Endo A, Yunome G, Harada A, Ooshio H, Kodama H, Takeda K, Kikuchi S: [Problems of adjuvant chemotherapy with S-1 for gastric cancer]. Gan To Kagaku Ryoho; 2010 Feb;37(2):255-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Problems of adjuvant chemotherapy with S-1 for gastric cancer].
  • From results of ACTS-GC,postoperative adjuvant chemotherapy,administration of S-1 for one year has become the standard for gastric cancer of Stage II and III except T1.
  • We inspected problems of adjuvant chemotherapy by S-1 by dose rate, an adverse event,and compliance.
  • For the period from July 2006 to December 2008,among 41 cases of stage II/stage III gastric cancer, S-1 was as started as adjuvant therapy by for 28 cases (68.3%).
  • Among 14 cases (63.6%) considered able to complete S-1 treatment for one year, 7 cases (31.8%) had to have their dose reduced or their administration schedule changed.
  • Thirteen patients took no S-1, and two (4.9%) of them took UFT, while 11 cases (26.8%) became a no-treatment follow-up group for reasons of age, coexisting symptoms and other reasons.
  • The problem in the future is to improve compliance, and to establish a treatment strategy for patients who do not meet administration criteria and for patients for whom continuation of drug administration is impossible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Oxonic Acid / adverse effects. Stomach Neoplasms / drug therapy. Tegafur / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / adverse effects. Drug Combinations. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154480.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


13. Imamura H, Anami S, Watanabe M, Kishimoto T, Miyazaki Y, Kato H, Usui T, Masutani S, Tomotsu K, Furukawa H: [Induction of liaison-clinical pathway for patients with gastric cancer undergoing adjuvant chemotherapy using S-1 after curative gastrectomy]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1361-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction of liaison-clinical pathway for patients with gastric cancer undergoing adjuvant chemotherapy using S-1 after curative gastrectomy].
  • The efficacy of adjuvant chemotherapy using S-1 for one year after curative surgical treatment for patients with gastric cancer of stage II or III was reported as the result of randomized controlled trial named ACTS-GC in 2007.
  • Therefore the number of patients undergoing this adjuvant chemotherapy is predicted to be rapidly increasing in near future.
  • On the other hand, the government promotes to construct the liaison-clinical pathway for patients with major carcinoma as a policy in 2007.
  • According to these two backgrounds, liaison-clinical pathway for patients with gastric cancer undergoing adjuvant chemotherapy using S-1 after curative gastrectomy has been induced in our institute from November 2007.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Critical Pathways. Gastrectomy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Drug Combinations. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701849.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


14. Saka M, Sasako M: [Informed consent for gastric cancer surgery]. Nihon Geka Gakkai Zasshi; 2007 Jan;108(1):10-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Informed consent for gastric cancer surgery].
  • Gastric cancer patients must have sufficient information on their prognosis and the risks and benefits associated with different therapeutic options before giving informed consent for treatment.
  • The clinical stage of the cancer should be explained, along with the possibility of stage migration after surgery.
  • The procedure proposed should be compared with other therapies including best supportive care, with explanations of postoperative prognosis, actual morbidity and mortality rates at the individual institution, and aftereffects.
  • Resected tissue is considered to be personal information, and consent must be obtained for its use in subsequent research after histopathologic examination.
  • Adjuvant chemotherapy using S-1 is a standard treatment option in advanced gastric cancer of stage II or III, for which patients should make an informed choice after sufficient explanations of its efficacy and adverse effects.
  • [MeSH-major] Informed Consent. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304951.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Nishida T, Yoshikawa M, Kitagawa T, Ito T, Matsuda H: Chemosensitivity test using collagen gel droplet-embedded culture may predict effectiveness of adjuvant therapy for gastric cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):4218

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemosensitivity test using collagen gel droplet-embedded culture may predict effectiveness of adjuvant therapy for gastric cancer.
  • : 4218 Background: The prediction of effectiveness of chemotherapy is important for patients' QOL and cost-effectiveness.
  • We conducted prospective multicenter study to evaluate chemosensitivity test using the collagen gel droplet-embedded culture (CD) system for 5FU-based adjuvant chemotherapy for the gastric cancer.
  • METHODS: Inclusion criteria are adults with stage II or III (JCGC) gastric cancer and good performance status (<2).
  • After written IC, fresh cancer specimens were obtained and cultured in the CD system with or without agents.
  • Following curative resection, 66 patients were registered and received the single protocol of 5FU-based adjuvant chemotherapy (two weeks i.v. therapy of 320 mg/m2 5FU and 5 mg/m2 CDDP, and one year oral intake of 200 mg/day 5FU).
  • RESULTS: Between the two groups, no differences in age, gender, PS, operative methods, lymph node dissection, pathological T, N, M, as well as stages, and histology, After 3 years follow-up, 20 patients of 28 in the resistant group recurred, and 9 patients of 27 in the sensitive group did (P=0.0069).
  • CONCLUSIONS: Chemosensitivity test may estimate disease-free survival of patients with stage II and III gastric cancers after adjuvant chemotherapy and may be useful to predict efficacy of adjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Sharma VB, Koong AC, Cho C, Mehta VK, Chen MC, Bastidas JA, Trueblood W, Fisher GA, Ford JM: Adjuvant chemoradiotherapy for T3, T4, or node positive gastric cancer: A phase II trial. J Clin Oncol; 2004 Jul 15;22(14_suppl):4139

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiotherapy for T3, T4, or node positive gastric cancer: A phase II trial.
  • : 4139 Background: Postoperative chemoradiotherapy using bolus 5FU has recently been established as the standard treatment of Stage II/III gastric cancer (Macdonald et. al., NEJM, 2001).
  • Here we report the preliminary results of a modified "Macdonald" regimen, incorporating carboplatin and utilizing the less toxic infusional 5FU regimen, in the adjuvant treatment for resected T3/T4 or node positive gastric cancer.
  • One to two weeks after completion of their radiation, patients then received an additional six weeks of chemotherapy identical to the first six weeks as tolerated.
  • Survival by stage was 80% (95% CI 63%-97%) for stage II (4 out of 5 patients alive); 70% (95% CI 50%-90%) for stage IIIA/IIIB (7 out of 10 patients alive); and 0% for stage IV disease (T3N3M0; 0 out of 4 patients alive).
  • CONCLUSION: In patients with advanced gastric cancer (T3/T4 or node positive disease) the addition of adjuvant chemoradiotherapy improves overall survival when compared to surgery alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014550.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Park SR, Lee JS, Kim YW, Choi IJ, Ryu KW, Lee JH, Lee JY, Park YL, Park SY, Park YI, Kim NK: Prognostic value of response assessed by RECIST and WHO criteria to neoadjuvant chemotherapy in locally advanced gastric cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15647

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of response assessed by RECIST and WHO criteria to neoadjuvant chemotherapy in locally advanced gastric cancer patients.
  • : e15647 Background: In metastatic gastric cancer, the response to chemotherapy is assessed by RECIST or WHO criteria according to the change of tumor size.
  • There are no data, however, on the usefulness of those criteria in evaluating tumor response in the setting of neoadjuvant chemotherapy.
  • The aim of this study was to evaluate the relationship between tumor response to neoadjuvant chemotherapy-as assessed by RECIST and WHO criteria-and clinical outcome in locally advanced gastric cancer (LAGC) patients.
  • METHODS: This study recruited LAGC patients who, from January 2003 through November 2005, entered the neoadjuvant arm of prospective randomized phase II trials comparing neoadjuvant chemotherapy to adjuvant chemotherapy.
  • LAGC was defined as stage III or IV (M0) disease based on computed tomography (CT) according to the Japanese Classification of Gastric Carcinoma.
  • Patients with measurable lesions received 3 cycles of neoadjuvant chemotherapy consisting of docetaxel (36 mg/m<sup>2</sup>) and cisplatin (40 mg/m<sup>2</sup>) on days 1 and 8 every 3 weeks, followed by surgery.
  • RESULTS: After chemotherapy, 40 (95%) patients underwent surgery and the remaining 2 patients showed new distant metastasis on CT scan.
  • Twenty-eight (67%) patients had a clinical response to neoadjuvant chemotherapy according to RECIST/WHO criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962733.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Jouhadi H, Sahraoui S, Acharki A, Benider A: Adjuvant chemotherapy for gastric carcinomas with positive lymph nodes: Experience with a weekly schedule of irinotecan + 5 FU + folinic acid. J Clin Oncol; 2004 Jul 15;22(14_suppl):4258

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for gastric carcinomas with positive lymph nodes: Experience with a weekly schedule of irinotecan + 5 FU + folinic acid.
  • : 4258 Background: Locally advanced gastric carcinoma is very frequent in Morocco.
  • In spite of a surgery often satisfactory and an adjuvant chemotherapy based on 5 FU+ Cisplatine, the 2 years survival remains low hardly passing the 50% .
  • METHODS: It is a prospective study led between September 2000 and September 2001 that included 34 patient with gastric carcinoma.
  • On the histological plan, 28 patients had a well differentiated adenocarcinoma and 6 patients an undifferentiated carcinoma.
  • The TNM stage was like follows: T3 in 29 cases and T4 in 5 cases; N1 in 19 cases, N2 in 10 cases and N3 in 5 cases.
  • The protocol of chemotherapy consisted in 8 weekly successive injections of: irinotecan 80 mg/m2 + 5 Fluorouracile: 750 mg/m2 + folinic acidic 20 mg/m2.
  • RESULTS: As regards to tolerance, a grade III neutropenia has been observed in 3 cases and a grade II diarrhea observed among 7 patients. at 2 years The disease free survival was 61%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014061.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Reichle A, Lugner A, Ott C, Klebl F, Vogelhuber M, Berand A, Andreesen R: Control of cancer-associated inflammation and survival: Results from a prospective randomized phase II trial in gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15584

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Control of cancer-associated inflammation and survival: Results from a prospective randomized phase II trial in gastric cancer.
  • : e15584 Background: An angiostatic approach was used to assess the impact of anti-inflammatory therapy in combination with metronomic low-dose chemotherapy.
  • METHODS: A randomized multi-institutional phase II trial was designed to select metronomic chemotherapy (arm A: capecitabine 1 g orally twice daily for 14 days with one week break until tumor progression) or combined anti-inflammatory/angiostatic treatment (arm B: capecitabine as mentioned above plus etoricoxib 60 mg orally, day 1+, and pioglitazone 60 mg orally, day 1+) for further evaluation.
  • Patients with refractory or progressive disease following any first-line therapy except capecitabine or frail were eligible.
  • According to the one stage design, a sample size of 64 patients was calculated for the primary objective, improvement of response rate.
  • In both treatment arms a significant decline of serum C-reactive protein (CRP) levels was observed within the first 4 to 6 weeks on treatment, A/B P= 0.01/0.04, respectively.
  • CONCLUSIONS: Metronomic low- dose chemotherapy in gastric cancer may induce anti-inflammatory response, but the chosen additional anti-inflammatory approach neither has impact on tumor-associated inflammation nor on response or survival rate.
  • In a historical comparison, CRP-responder have similar outcome as patients treated with combination chemotherapy in first-line.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962359.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Escudero MP, Alonso V, Valencia J, Lastra R, Grandez R, Polo S, Ruiz de Lobera A, Polo E, Anton A, Tres A: Adjuvant postoperative chemoradiotherapy in gastric carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):4168

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant postoperative chemoradiotherapy in gastric carcinoma.
  • : 4168 Background: To evaluate the impact of postoperative external radiation therapy combined with 5-Fluorouracil (5FU)-based chemotherapy on the disease-free and overall survival of patients with resected gastric adenocarcinoma.
  • METHODS: Patients with pathological T3/T4 or N+ gastric adenocarcinoma were treated with postgastrectomy chemoradiotherapy.
  • External radiotherapy was administered to the tumor bed and regional nodes, and 2 cm beyond the proximal and distal margins of resection (45 Gy/25 fractions).
  • Chemotherapy: Group A: 5-FU 425 mg/m<sup>2</sup>/d + LV 20 mg/m<sup>2</sup> on days 1-5 every four weeks for two cycles before and after radiation therapy.
  • During radiation therapy with 5-FU protracted continuous infusion (225 mg/m<sup>2</sup>/d) was administered.
  • Group B: Mitomicin C 20 mg/m<sup>2</sup> on day 1 (single dose) followed by Tegafur 500 mg/m<sup>2</sup>/d for six months, even during radiation therapy Results: 40 patients have been included (20 group A, 20 group B).
  • Pathologic stage: II 12p, IIIA 14p, IIIB 7p, IV-M0 7p.
  • The locoregional relapse rate was low probably due to the radiation therapy addition.
  • However the distant metastases rate and the median overall survival seem to be hardly modified by the treatment.
  • We need to find a better scheme of chemotherapy for further studies in order to improve these results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013766.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kang S, Hwang Y, Lee H, Jeong S, Choi J, Jo Y, Han S, Kim J, Han J: Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer with curative resection. J Clin Oncol; 2009 May 20;27(15_suppl):4562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer with curative resection.
  • : 4562 Background: A few studies reported the association between helicobacter pylori (HP) infection and better overall survival (OS) in resected gastric cancer patients (pts).
  • METHODS: We investigated the HP infection status and its association with clinicopathologic characteristics in 210 locally advanced gastric cancer patients (stage IB: 18, II: 61, IIIA: 62, IIIB: 31, IV: 38) who underwent adjuvant chemotherapy (CTX) after curative resection (≥D2 dissection).
  • HP infection status in hematoxlin and eosin stained peritumoral tissue was graded according to the updated Sydney System and categorized as HP(-) (normal or mild infection) and HP(+) (moderate or marked infection) (Am J Surg Pathol 20:1161, 1996).
  • Twenty-two pts received 5-FU, doxorubicin (DOX) CTX (5- FU 500 mg/m2 weekly for 36 wks, DOX 40 mg/m2 q 3 weeks x 12) with or without OK432, while 188 pts underwent 5-FU, mitomycin-C (MMC), and polysaccharide-K (PSK) CTX (5-FU 500 mg/m2 weekly for 24 wks, MMC 8 mg/m2 q 6 wks x 4, PSK 3 g/day for 16 wks) (Br J Cancer 84:186, 2001, Hepatogastroenterol 54:290, 2007).
  • HP (-) was significantly correlated with Bormann type IV, larger tumor size (>5.5cm),and stage IIIB.
  • HP(-) was associated with poor outcome in all stages except stage IB (p=0.075).
  • In multivariate analysis, HP(-) was the most significant independent prognostic factor of poor OS (hazard ratio 9.646, 95% CI 5.407-17.206, p<0.0001) followed by advanced stage (p=0.032), Bormann type IV (p=0.037) and old age (p=0.015).
  • CONCLUSIONS: HP infection status seems to have strong prognostic significance in locally advanced gastric cancer.
  • HP (-) pts may need intensified adjuvant treatment and careful follow-up.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963058.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Iwasa S, Yamada Y, Nakajima TE, Kato K, Hamaguchi T, Morita S, Saka M, Fukagawa T, Katai H, Shimada Y: Predictive factors of outcome and clinical management of adjuvant S-1 chemotherapy for gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15676

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of outcome and clinical management of adjuvant S-1 chemotherapy for gastric cancer.
  • : e15676 Background: Adjuvant S-1 chemotherapy has become a standard treatment for stage II and III gastric cancer, following the Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC).
  • This study was designed to identify factors that can be used for predicting the outcome and clinical management of adjuvant S-1 chemotherapy in patients with stage II and III gastric cancer.
  • METHODS: We retrospectively examined 97 consecutive patients with stage II or III gastric cancer who received S-1 chemotherapy after gastrectomy to investigate factors associated with outcome and clinical management.
  • As for adjuvant S-1 chemotherapy, dose reduction and dose schedule modification were conducted in 59% and 40% of the patients, respectively.
  • Of the patients needing dose reduction, 79% underwent reduction within three months of treatment.
  • The most common reason for dose reduction during the treatment period was anorexia (47%), followed by diarrhea (32%), leukopenia (24%) and rash (16%) with overlapping reasons.
  • The duration period of the treatment was at least 3 months in 88%, at least 6 months in 82%, and scheduled 12 months in 73%.
  • Twenty six patients discontinued treatment due to adverse event (20 patients), recurrent disease (2 patients) and other reasons (4 patients).
  • The median duration until treatment discontinuation was 4.0 months.
  • CONCLUSIONS: Most patients (73%) could complete the scheduled treatment duration by dose reduction and dose schedule modification.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962827.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Song H, Kim J, Do Y, Lee W, Ryu S, Kim I, Sohn S: The clinical significance of oophorectomy in gastric patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15646

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical significance of oophorectomy in gastric patients.
  • : e15646 Background: The oophorectomy in isolated metastasis of ovary can lead to long term survival in patients with gastric cancer, but the clinical significance of oophorectomy in stage IV gastric cancer patients is not known well in this time.
  • METHODS: We reviewed the medical record of the 55 gastric cancer patients who were metastasis or recurrent in ovary at Dongsan Medical Center, Kimyung University School of Medicine, Daegu, Korea from 1985 to 2008.
  • RESULTS: Twenty-one patients were metastasis to ovary at the time of diagnosis of gastric cancer, and 34 patients were recurrent in ovary after the gastric resection.
  • The mean age was 45.3 ± 11.6 years in metastatic cancer and 46.8 ±12.6 years in recurrent cancer patients.
  • The stage at the time of gastric resection in 34 recurrent patients were I in 3, II in 1, III in 18, and IV in 10.
  • Adjuvant chemotherapy were performed in 26 (76.5%) patients.
  • Oophorectomy were performed in 33 (97.1%) of recurrent cancer, and 17 (81.0%) of metastatic cancer.
  • The 1-year and 2-year survival rate of metastatic cancer were 14.7%, and 0%, and 1-year, 2-year, and 3-year survival rate of recurrent cancer were 47.2%, 18.1%, and 0%, respectively.
  • The median survival duration of metastatic cancer were 8.9 ±1.0 months, and recurrent cancer were 11.4 ±2.3 months.
  • Recurrent cancer were better survival than metastatic cancer patients (p=0.014).
  • The long-term survival (over 2 years) was noted in 5 patients of recurrent cancer patients.
  • The stage of gastric cancer was correlated to overall survival time in total patients (p=0.028).
  • But, the relapse-free survival time after gastrectomy is the only factor to predict survival duration after oophorectomy in recurrent cancer patients (p=0.029).
  • Age, stage of gastric cancer, extent of involvement of ovary, and systemic chemotherapy were not related to survival time of recurrent cancer patients.
  • CONCLUSIONS: The survival time in patients with oophorectomy in recurrent gastric cancer was correlated to relapse-free survival time after gastric resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962732.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Wu S, Deng X, Zhang P, Xie C, Zhang X, Jin Z: Phase II study of postoperative chemoradiotherapy for esophageal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15606

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of postoperative chemoradiotherapy for esophageal carcinoma.
  • : e15606 Background: Esophageal squamous cell carcinoma is still a virulent disease diagnosed at late stage and remains a major cause of carcinoma mortality in China.
  • The preoperative chemoradiotherapy had been applied to patients with esophageal carcinoma in an effort to reduce the relapse and improve survival.
  • Intergroup study 0116 demonstrated that postoperative chemoradiotherapy significantly improved overall survival in gastric carcinoma patients.
  • The question remains whether postoperative chemoradiotherapy can improve overall survival in patients with esophageal carcinoma.
  • Our planning study was to investigate the role of postoperative chemoradiotherapy in the multimodality treatment for locally advanced esophageal carcinoma.
  • METHODS: From October 2000 to October 2007, Fifty-two patients who underwent esophagectomy with stage II-III esophageal carcinoma were enrolled.
  • Two cycles of chemotherapy (Paclitaxel 135mg/m<sup>2</sup> d1,cisplatin 20mg/m<sup>2</sup>d1-3) were administered concurrently on days 1-3 and days 29-31 of radiotherapy.
  • RESULTS: Of the total 52 patients, 28 (54%) developed grade 3 or 4 toxicity.At the time of analysis, 23 patients died.
  • The median survival time was 37.2 months.
  • CONCLUSIONS: This novel postoperative chemoradiation regimen for treatment of patients with stage II-III esophageal cancer has a tolerable toxicity and promising 3-year overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962684.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Bokemeyer C, Kollmannsberger C, Budach W, Stahl M, Schleucher N, Hehr T, Wilke HJ, Vanhoefer U, Schleicher J, Kanz L: Adjuvant radiochemotherapy (RTx/CTx) using 5-FU/Folinic acid (FA) /cisplatin (DDP) ± paclitaxel (P) and radiation in patients (pts) with completely (R0) resected high-risk gastric cancer (UICC stages II-IV (M0): An extended phase II study of the AIO/ARO/ACO. J Clin Oncol; 2004 Jul 15;22(14_suppl):4036

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiochemotherapy (RTx/CTx) using 5-FU/Folinic acid (FA) /cisplatin (DDP) ± paclitaxel (P) and radiation in patients (pts) with completely (R0) resected high-risk gastric cancer (UICC stages II-IV (M0): An extended phase II study of the AIO/ARO/ACO.
  • : 4036 Background: The US-Intergroup study 0116 has demonstrated a significant survival benefit for pts receiving adjuvant Rtx/CTx following complete resection of gastric cancer.
  • The current study evaluates the feasibility, toxicity and efficacy of a novel adjuvant combined modality treatment strategy containing a 3-4-drug chemotherapy regimen (CTx) plus 5-FU-based RTx/CTx.
  • Treatment consisted of 2 cycles of FA 500 mg/m<sup>2</sup> (2h) / 5-FU 2000 mg/m<sup>2</sup> (24h) once weekly for 6 consecutive weeks, P 175 mg/m<sup>2</sup> (3h) weeks 1 and 4 and DDP 50 mg/m<sup>2</sup> (1h) weeks 2 and 5 or 2 cycles of FA 500 mg/m<sup>2</sup> (2h) / 5-FU 2000 mg/m<sup>2</sup> (24h) once weekly for 6 consecutive weeks with DDP 50 mg/m<sup>2</sup> (1h) weeks 1,3,5.
  • Radiation therapy with 45 Gy plus concomitantly applied 5-FU 225mg/m<sup>2</sup>/24h was scheduled in between the 2 cycles.
  • Pts with completely resected adenocarcinoma of the stomach including a systematic D1 or D2 lymph node dissection (LND) were eligible.
  • RESULTS: Treatment: FA/5-FU/P/DDP 44 pts; FA/5-FU/DDP 52 pts.
  • Pts characteristics: median age: 52 years [25-69]; extended/total/subtotal gastrectomy 38%/49%/13%; D1/D2 LND 31%/69%, stage distribution: UICC stage II 36%, IIIA 25%, IIIB 18%, IV(M0) 21%.
  • CONCLUSIONS: These novel RTx/CTx regimens appear feasible and safe with acceptable toxicity indicating that DDp can be safely added to 5-FU/FA and that even a 3-drug regimen is a feasible treatment option for adjuvant radiochemotherapy in gastric cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014393.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Okazaki K, Kira M, Yamai H, Nakagawa Y, Nagao T, Kenzaki K, Bando Y, Morimoto T, Kondo K, Tangoku A: Phase II trial report of the new neoadjuvant chemotherapy with S-1 and docetaxel for advanced breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):1121

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial report of the new neoadjuvant chemotherapy with S-1 and docetaxel for advanced breast cancer.
  • : 1121 Background: Primary chemotherapy with anthracycline and taxanes is a gold standard regimen which realize pathologically complete response in 20% of patients with advanced breast cancer.
  • S-1 is a new oral anti-tumor drug, which is composed of 5-fluoro-1-(tetrahydro -2- furanyl)-2, 4(1H, 3H)-pyrimidinedione (Tegafur, FT), 5-chloro-2, 4- dihydroxypyridine (Gimeracil, CDHP) and potassium 1, 2, 3, 4-tetrahydro-2, 4-dioxo-1, 3, 5-triazine-6-carboxylate (potassium Oteracil, Oxo).
  • Combined treatment with docetaxel and S-1 yielded significant response in patients with gastric cancer with minimal side effects due to biochemical modulation of both CDHP and Oxo.
  • The purpose of this study was to evaluate the efficacy and toxicity of docetaxel in combination with S-1 for advanced breast cancer.
  • METHODS: Patients with advanced breast cancer (Stage IIA to IV) were treated with i.v. docetaxel (40mg/m<sup>2</sup>) on day 1 and oral S-1(80mg as FT/m<sup>2</sup>/day) on days 1 to 14 every 3 weeks for 8 courses.
  • The patients underwent surgery after completion of chemotherapy.
  • RESULTS: Twenty-two patients completed the therapy and underwent surgery.
  • CONCLUSIONS: The new regimen of S-1 combined with docetaxel is expected to exhibit satisfactory efficacy in treating advanced breast cancer as primary chemotherapy.
  • Genetic analysis will be performed to examine and to find biomarkers for measurement of the efficacy of this therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962232.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Altinbas M, Kaplan B, Ucar K, Ozkan M, Karahacioglu E, Er O, Kucuk C, Soyuer I: 5-FU plus leucovorin (Mayo Regimen) for concurrent chemoradiotherapy after surgery in patients with resectable locally advanced gastric carcinoma: Preliminary results of a phase II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):4196

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-FU plus leucovorin (Mayo Regimen) for concurrent chemoradiotherapy after surgery in patients with resectable locally advanced gastric carcinoma: Preliminary results of a phase II study.
  • : 4196 Background: Patients with locoregionally advanced carcinoma of the stomach have a grim outcome due to frequent local and systemic recurrences after surgery.
  • To potentially increase the local control or survival rate and decrease relapses, we investigated a strategy of concurrent chemoradiotherapy and followed by consolidation chemotherapy after surgery.
  • METHODS: Operable 71 patients (Stage IB-IV, M0) underwent total or subtotal gastrectomy.
  • Adjuvant chemotherapy (250 mg/m2 5-FU) was administered concurrently on the first day of every radiotherapy weeks [which was totally standart field radiotherapy (RT), or total abdominal field RT up to 20 Gy first, then returned to standart field RT], .
  • After chemoradiotherapy regimen, consolidation chemotherapy consisted of 450 mg/mg 5-FU plus 20 mg/m2 Leucovorin was applied up to four cycles, q28 d.
  • There were not significant difference between two arms according to the age, sex, surgical approach, tumor localization, and stages.
  • Six patients in both arms did not get consolidation chemotherapy.
  • One-year progression-free survival was 53% and 65% on the first and second arm, respectively.
  • The overall survival was 63% and 70% on the first and second arm, respectively.
  • Nine patients (24%) on the first, and 12 (40%), and on the second arm were died.
  • Commonest side effects during chemoradiotherapy were grade 3-4 neutropenia on the first arm (14%), diarrhea on the second arm (17%).
  • There were no deaths related to chemotherapy, chemoradiotherapy, or surgery.
  • CONCLUSIONS: Preliminary results suggest the feasibility of postoperative adjuvant chemoradiotherapy with 5-FU followed by consolidation chomotherapy with MAYO regimen in gastric cancer with acceptable toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013890.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Ji JF, Yu Z, Zhong XN, Wu XJ, Wu Q, Bu ZD, Wang Y: Oxaliplatin-based regimen as neoadjuvant chemotherapy for Chinese patients with advanced gastric cancer: Preliminary results of a phase II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):4184

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin-based regimen as neoadjuvant chemotherapy for Chinese patients with advanced gastric cancer: Preliminary results of a phase II study.
  • : 4184 Background: Gastric cancer is the first cause of death per cancer in China, with more than 160,000 deaths/year.
  • At time of resection, 75-85% of gastric cancer (GC) patients (pts) are expected to have nodal involvement and are at high risk of postoperative relapse.
  • A Phase-II trial was conducted to evaluate the benefits of surgery combined with Oxaliplatin (OXA)-based regimen as neoadjuvant and adjuvant chemotherapy, on the survival of pts with locally advanced disease.
  • METHODS: 15 pts (Stage IIIb or IV) have been enrolled by now.
  • All pts had histologically proven gastric adenocarcinoma and no previous palliative chemotherapy.
  • RESULTS: All pts are evaluable for response with a more than 50% tumor reduction in 7 of 15 (46.7%)pts, SD was observed in 6 pts (40.0%) and PD in 2(13.3%).14 of 15 pts received a total 6 cycles (pre-op +or- post-op) of chemotherapy and all 15 pts came to surgery after receiving 2-6 cycles.
  • There were no postoperative mortalities and no treatment related deaths; 14 of 15 pts are surviving (2 to 24 months) and one PD pt died of disease 2 months after surgery.
  • Pathologic examinations of operative samples showed significant chemotherapy-induced changes in 6 pts.
  • CONCLUSIONS: In view of the favorable response rate and toxicity profile, this protocol will be further assessed in a multicenter phase II trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013812.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Broome P, Buck RD, Michaeli D: Immune response to Gastrin-17 is an independent covariate in determination of survival in colorectal, gastric and pancreatic cancers. J Clin Oncol; 2004 Jul 15;22(14_suppl):4073

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune response to Gastrin-17 is an independent covariate in determination of survival in colorectal, gastric and pancreatic cancers.
  • The relationships of demographics, tumor stage at onset, number and location of metastases, baseline Karnofsky performance status (KPS) and laboratory values to immune response were examined in each study; their joint relationships with immune response on survival was analyzed using Cox regression analysis.
  • RESULTS: In 158 metastatic colorectal cancer patients who had previously failed chemotherapy, median survival (MS) was 227 days; MS of G17 responders was 249 days vs. 119 days for non-responders (p<0.001, log-rank).
  • For 102 advanced gastric cancer patients on chemo-immunotherapy, MS was 265 days; for G17 responders, 303 days vs. 70 days for non-responders (p<0.001, log-rank).
  • In a placebo-controlled trial in 152 stage II-IV pancreatic cancer patients, MS was 111 days; MS of G17 responders was 176 days, of non-responders 63 days and of the placebo group 83 days (p=0.028, log-rank).
  • With the exception of race (for colorectal cancer) and KPS, no parameter significantly affected the antibody response to G17.
  • CONCLUSIONS: Subjects with advanced colorectal, gastric or pancreatic cancers, who generated antibodies to G17 following immunization with G17DT, had a significantly prolonged survival compared to those who did not.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014400.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Fujitani K, Tamura S, Kimura Y, Tsuji T, Matsuyama J, Iijima S, Imamura H, Kurokawa Y, Tsujinaka T, Furukawa H: Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy (OGSG 0604). J Clin Oncol; 2009 May 20;27(15_suppl):e15567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy (OGSG 0604).
  • : e15567 Background: Although an adjuvant chemotherapy with S-1 has become the standard treatment for stage II-III gastric cancer (GC) patients (pts) after curative D2 gastrectomy in Japan, the survival benefit for stage III pts obtained by S-1 is considered to be modest.
  • This phase II study evaluated the feasibility and safety of adjuvant S-1 plus docetaxel for stage III GC pts after R0 resection.
  • METHODS: Patients with curatively resected pathological stage III GC receiving D2 dissection, age 20-80 years, performance status < 1, no prior adjuvant treatment, adequate organ function, and informed consent were given S-1 (80 mg/m<sup>2</sup>/day) orally for consecutive 2 weeks plus docetaxel (40 mg/m<sup>2</sup>) intravenously on day 1, repeated every 3 weeks.
  • The treatment was started within 45 days after gastrectomy, and repeated for 4 cycles, followed by S-1 monotherapy until 1 year after surgery.
  • Pathological stages included IIIA in 36 pts and IIIB in 17 pts.
  • Planned 4 cycles of treatment were delivered to 41 out of 53 pts, with the feasibility of 77.4% (95% CI 63.8-87.7%, P<0.001).
  • Reasons for discontinuation were recurrent cancer in 1 pt, adverse events in 10, and miscellaneous in 1, respectively.
  • No treatment-related deaths occurred.
  • Although follow-up is ongoing on survival, this regimen could be a candidate of future phase III trial seeking for the optimal adjuvant chemotherapy for stage III GC pts after curative D2 gastrectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962326.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR: The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer; 2008;11(1):1-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies.
  • Perioperative chemotherapy in stage II and stage III gastric cancer is now accepted as a standard of care in the Western world.
  • Two randomized phase III studies have shown improved survival for patients with induction chemotherapy followed by surgery compared with surgery alone.
  • It is generally accepted that patients who respond to induction therapy have a significantly improved survival compared with that in nonresponding patients.
  • In adenocarcinomas of the esophagogastric junction (AEG), fluorodeoxyglucose-positron emission tomography (FDG-PET) prospectively was established as a surrogate predicting response and prognosis.
  • The MUNICON (Metabolic response evalUatioN for Individualisation of neoadjuvant Chemotherapy in oesOphageal and oesophagogastric adeNocarcinoma) I study confirmed prospectively the usefulness of early metabolic response evaluation and showed the feasibility of a PET-guided treatment algorithm.
  • These findings are an important step forward in the tailoring of multimodal treatment in accordance with tumor biology.
  • In gastric cancer, we have analyzed FDG-PET in a prospective study.
  • In gastric cancer the issue is more complicated, because about 30% of gastric cancers cannot be visualized with sufficient contrast for quantification.
  • Insufficient FDG uptake is mostly associated with diffuse-type gastric cancer with signet ring cells and mucinous content.
  • Treatment concepts such as immediate resection after only 2 weeks of induction therapy with or without adjuvant treatment could be considered in metabolic nonresponders, or modified chemotherapy regimens, possibly including biologically targeted drugs, could be considered in those with FDG-nonavid tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoadjuvant Therapy / methods. Positron-Emission Tomography. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Contrast Media. Disease Progression. Fluorodeoxyglucose F18. Humans. Neoplasm Staging. Prognosis. Radiopharmaceuticals. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2365-72 [16245310.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):624-8; discussion 628-31 [17893499.001]
  • [Cites] J Clin Oncol. 1999 Aug;17 (8):2403-11 [10561303.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):148-55 [16228236.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):279-86 [11466680.001]
  • [Cites] Radiology. 2006 May;239(2):472-80 [16543584.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12 ):3058-65 [11408502.001]
  • [Cites] J Nucl Med. 2005 Dec;46(12 ):2029-34 [16330567.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):303-8 [10077040.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2089-97 [8374867.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] Gastric Cancer. 2003;6(3):159-67 [14520529.001]
  • [Cites] Surg Oncol Clin N Am. 2000 Jan;9(1):97-117, vii-viii [10601527.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2307-15 [12796400.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] J Nucl Med. 2005 Oct;46(10 ):1582-8 [16204706.001]
  • [Cites] Ann Surg. 2005 May;241(5):810-7; discussion 817-20 [15849517.001]
  • [Cites] Jpn J Clin Oncol. 2003 Oct;33(10):533-7 [14623923.001]
  • [Cites] Gastric Cancer. 2000 Dec 27;3(3):128-133 [11984725.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2006 May 15;44(10 ):661-4 [16784672.001]
  • [Cites] Nucl Med Commun. 2004 Aug;25(8):825-31 [15266178.001]
  • [Cites] World J Surg. 2004 Mar;28(3):247-53 [14961197.001]
  • [Cites] Gastric Cancer. 2006;9(3):192-6 [16952037.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60 [15464463.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2383-90 [15856477.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 Dec;27(14):2179-84 [11142160.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Feb;59(3):313-20 [16770582.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):918-27 [11251943.001]
  • [Cites] Ann Surg Oncol. 2001 Jul;8(6):519-24 [11456051.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1281-6 [16622464.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):288-95 [12552348.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 18373171.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 42
  •  go-up   go-down


32. Zuo Y, Xu M, Shen D, Lu WD, Lu JF: [Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients]. Zhonghua Zhong Liu Za Zhi; 2004 Apr;26(4):247-9
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients].
  • OBJECTIVE: To evaluate the efficacy of postoperative intraperitoneal hyperthermic chemoperfusion (IHCP) combined with intravenous chemotherapy for advanced gastric cancer.
  • METHODS: Eighty-two patients with stage II - IV gastric cancer were postoperatively randomized into two groups; 46 patients in treatment group who received IHCP combined with intravenous chemotherapy for three times and 36 patients in control group who received intravenous chemotherapy only for six times.
  • All patients in the two groups received the same chemo-regimen LFAP (CF + 5-Fu + THP or MIT + PDD) 21 - 28 days after operation.
  • RESULTS: The 1-year survival rate was 98% (45/46) in the treatment group and 94% (34/36) in the control group without any significant difference (P > 0.05).
  • The 3-year survival rate was 83% (38/46) in the treatment group and 61% (22/36) in the control group with significant difference (P < 0.05).
  • Gastrointestinal reaction in the treatment group was significantly decreased compared with in the control group (37% vs 80%, P < 0.01), whereas no statistically significant difference was noted in bone marrow suppression (P > 0.05).
  • CONCLUSION: Intraperitoneal hyperthermic chemoperfusion combined with intravenous chemotherapy can prolong survival and reduce gastrointestinal side-effect which provides an effective treatment option for advanced gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperthermia, Induced / methods. Stomach Neoplasms / therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Infusions, Parenteral. Injections, Intravenous. Leucovorin / administration & dosage. Male. Middle Aged. Mitoxantrone / administration & dosage. Neoplasm Staging. Postoperative Period. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15312391.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] BZ114NVM5P / Mitoxantrone; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


33. Fujitani K, Kobayashi K, Tamaki Y, Tsujinaka T, Hirao M: [Adjuvant chemotherapy after curative resection for gastric cancer-5'-DFUR + cisplatin vs 5'-DFUR]. Gan To Kagaku Ryoho; 2002 Jan;29(1):61-5
Hazardous Substances Data Bank. FLOXURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy after curative resection for gastric cancer-5'-DFUR + cisplatin vs 5'-DFUR].
  • A prospective randomized study involving gastric cancer patients was conducted to evaluate combined adjuvant chemotherapy.
  • Forty-two patients under 80 years of age who underwent a curative resection of pathologic stage II or III gastric cancer were randomly assigned to receive adjuvant chemotherapy containing the following two regimens from 1993 to 1996.
  • In stage III patients, the 5-year disease-free survival rates were 55.6% in A and 20.7% in B (p = 0.26).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Floxuridine / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Gastrectomy. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11816479.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; Q20Q21Q62J / Cisplatin; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


34. Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M: Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer. Oncol Rep; 2009 Jun;21(6):1467-75
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer.
  • Phosphatase of regenerating liver-3 (PRL-3) has received attention as a molecule associated with metastasis in various tumor types, including gastric cancer.
  • However, its clinical utility as a biomarker remains unclear in primary gastric cancer.
  • The present study included 173 patients with primary gastric cancer who underwent gastrectomy with regional lymphadenectomy at the Kitasato University Hospital.
  • PRL-3 overexpression was detected in 78 (45%) of 173 primary tumor tissues and was an independent predictor of lymph node metastasis on multivariate logistic regression analysis (odds ratio=9.32; P<0.0001).
  • Moreover, in advanced gastric cancer with stage I disease, PRL-3 overexpression inversely affected patient outcome (P=0.02) and showed a characteristic of stage II disease from a prognostic point of view.
  • We demonstrated for the first time that PRL-3 expression in primary tumor could predict the outcome of patients with histologically node-negative gastric cancer.
  • We propose that PRL-3 expression can have a clinical potential as a prognostic biomarker that may facilitate the development of adjuvant chemotherapy for advanced gastric cancer with stage I disease.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Protein Tyrosine Phosphatases / analysis. Stomach Neoplasms / enzymology
  • [MeSH-minor] Female. Gastrectomy. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Logistic Models. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Predictive Value of Tests. Risk Assessment. Time Factors. Treatment Outcome. Up-Regulation

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424625.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


35. Sakurai Y, Kamoshida S, Furuta S, Sunagawa R, Inaba K, Isogaki J, Komori Y, Uyama I, Tsutsumi Y: [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy]. Gan To Kagaku Ryoho; 2008 Jul;35(7):1147-55
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Predictive value of orotate phosphoribosyltransferase in chemoresistant patients with gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy].
  • S-1, a most effective DPD-inhibitory fluoropyrimidine, used as neoadjuvant/adjuvant chemotherapy has recently been shown to improve clinical outcome in patients with stage II and III advanced stage gastric carcinoma.
  • Orotate phosphoribosyltransferase(OPRTEC 2.4.2.10)is a primary enzyme involved in the first-step phosphorylation process of 5-fluorouracil and is an important enzyme that possibly enables to predict sensitivity to S-1 irrespective of tissue DPD levels.
  • To test the hypothesis that a low OPRT level in gastric carcinoma tissue is an indicator of chemoresistance to S-1-based chemotherapy, the predictive value of OPRT levels in chemoresistance was evaluated in patients with gastric carcinoma undergoing S-1-based-neoadjuvant/adjuvant chemotherapy using survival analyses.
  • A total of 67 patients with advanced-stage gastric carcinoma who underwent S-1-based neoadjuvant/adjuvant chemotherapy were subjected to the study.
  • The OPRT level was determined by an enzyme-linked immunosorbent assay(ELISA)that has recently been developed.
  • The patients who underwent S-1-based adjuvant/neoadjuvant chemotherapy(n=67)were divided into 2 groups using various cut-off values to determine the prognostic significance of the OPRT level.
  • The P value of the survival rate between the groups of low and high OPRT levels was the lowest(p=0.0018), when 2.0 ng/mg protein was used as a cut-off value for the OPRT level.
  • In particular, there was a significant difference in the survival rates between Group L and Group H in stage III patients(p<0.05 by logrank test).
  • The multivariate analysis using Cox' proportional hazard model indicated that venous invasion of carcinoma(>v2), lymph node metastasis(>5), and low OPRT level (OPRT<2.0 ng/mg protein) were significant prognostic factors in patients who were underwent S-1-based neoadjuvant/adjuvant chemotherapy.
  • These results suggest that patients with a low OPRT level(OPRT<2.0 ng/mg protein)are non-responders to S-1- based adjuvant/neoadjuvant chemotherapy.
  • The determination of OPRT levels in gastric carcinoma tissue enables to predict the response to S-1-based neoadjuvant/adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm / drug effects. Orotate Phosphoribosyltransferase / metabolism. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / enzymology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Drug Combinations. Female. Humans. Male. Neoadjuvant Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633253.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 2.4.2.10 / Orotate Phosphoribosyltransferase
  •  go-up   go-down


36. Tanaka H, Muguruma K, Kubo N, Amano R, Noda E, Yamada N, Yashiro M, Maeda K, Sawada T, Ohira M, Ishikawa T, Hirakawa K: [Effect of PSK on recurrence of stage II/III gastric cancer]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2258-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of PSK on recurrence of stage II/III gastric cancer].
  • In Japan, PSK has been used as an adjuvant chemotherapeutic drug against gastric cancer.
  • The aim of this study was to evaluate the impact of PSK on postoperative recurrence in patients with gastric cancer.
  • The patients with Stage II/III gastric cancer who underwent a surgical curative resection between 1999 and 2008 at the Department of Surgical Oncology, Osaka City University were included in this retrospective study.
  • Our results suggested that a population with venous infiltration of primary lesion should be at risk of recurrence after surgery even if PSK was administered as postoperative adjuvant therapy.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Proteoglycans / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224540.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Proteoglycans; 66455-27-4 / krestin
  •  go-up   go-down


37. Fujii M, Kochi M, Takayama T: Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today; 2010 Apr;40(4):295-300
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in chemotherapy for advanced gastric cancer in Japan.
  • In the early 1990s, a combination of 5-fluorouracil (5-FU) and cisplatin was widely adopted to treat advanced gastric cancer; however, no survival advantage over single-agent 5-FU was confirmed by the results of randomized trials conducted over a long period.
  • Recently developed agents such as irinotecan, taxanes (docetaxel), and new oral fluorouracil (S-1) have yielded more promising results, with a response rate of over 50% and a median survival time of over 10 months in combination studies.
  • Based on the findings of a large randomized study, S-1 has become standard in the adjuvant setting after D2 dissection curatively resected stage II and III gastric cancer.
  • This article reviews the recent advances in gastric cancer chemotherapy, especially in Japan.
  • [MeSH-major] Stomach Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2007 Dec;94(12):1468-76 [17948223.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):54-9 [12506170.001]
  • [Cites] Cancer Treat Rep. 1982 Jun;66(6):1263-6 [7083233.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1803-8 [16773074.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1871-6 [393382.001]
  • [Cites] Oncology. 2008;75(1-2):1-7 [18719348.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3402-7 [16740764.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:131-4 [16897988.001]
  • [Cites] Int J Clin Oncol. 2008 Jun;13(3):201-5 [18553228.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1863-9 [393381.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):269-72 [10390007.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Cancer Treat Rev. 1988 Dec;15(4):257-77 [3071419.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):319-23 [10458249.001]
  • (PMID = 20339982.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 25
  •  go-up   go-down


38. Topuz E, Basaran M, Saip P, Aydiner A, Argon A, Sakar B, Tas F, Uygun K, Bugra D, Aykan NF: Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study. Am J Clin Oncol; 2002 Dec;25(6):619-24
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study.
  • Gastric carcinoma remains one of the leading causes of cancer-related death in the world.
  • Clinical studies have revealed that approximately two thirds of the patients seek treatment for early recurrence within the abdominal cavity.
  • The aim of this phase II study was to evaluate the toxicity, feasibility, and efficacy of adjuvant intraperitoneal chemotherapy (IPCT) with cisplatin, mitoxantrone, 5-fluorouracil (5-FU), and folinic acid in patients with stage II-III gastric cancer.
  • Patients with stage II and III gastric cancer aged between 15 and 70 years, after curative resection, with adequate liver, renal, and cardiac function were included in the study.
  • The chemotherapy regimen consisted of cisplatin 60 mg/m2, mitoxantrone 12 mg/m2, 5-FU 600 mg/m2, and folinic acid 60 mg/m2, delivered intraperitoneally, diluted in 2 l normal saline.
  • However, adjuvant IPCT has similar survival rates in comparison to no adjuvant treatment; thus, it cannot be currently recommended outside the context of a clinical trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Infusions, Parenteral. Leucovorin / administration & dosage. Male. Middle Aged. Mitoxantrone / administration & dosage. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12478012.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BZ114NVM5P / Mitoxantrone; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


39. Fukuda N, Sugiyama Y, Wada J, Niki M, Nomoto T: [A case of advanced gastric cancer successfully treated with S-1 and paclitaxel followed by curative resection]. Gan To Kagaku Ryoho; 2008 Aug;35(8):1379-82
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer successfully treated with S-1 and paclitaxel followed by curative resection].
  • A 59-year-old man diagnosed with Stage IV advanced gastric cancer due to pancreatic invasion(T4)and splenic hilum lymph node metastasis(N3)was initially treated with neoadjuvant chemotherapy using S-1 and CDDP.
  • After 4 courses, CT scan revealed reduced tumor size and the disappearance of splenic hilum lymph node swelling that indicated PR of the chemotherapy.
  • He could undergo subtotal gastrectomy(Billroth II)with lymph node dissection(D2)and cholecystectomy.
  • Histopathological examination revealed Stage II (pT2(SS), pN1, CY0, ly1, v2)advanced gastric cancer that showed good effect of S-1 and paclitaxel.
  • Neoadjuvant chemotherapy using S-1 and paclitaxel for advanced gastric cancer seems to have been effective.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Oxonic Acid / therapeutic use. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Carcinoembryonic Antigen / blood. Cholecystectomy. Drug Combinations. Gastrectomy. Gastroscopy. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701853.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


40. Tanida T, Aoki T, Igarashi Y, Tsukao Y, Komori T, Matsumoto T, Takachi K, Nishioka K, Uemura Y, Kobayashi K: [Two cases of long-term survival with CY1, stage IV gastric cancer due to surgery and postoperative chemotherapy]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2063-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of long-term survival with CY1, stage IV gastric cancer due to surgery and postoperative chemotherapy].
  • The first case is a man in his 30s with gastric cancer, of which clinical finding was T3N0M0P0M0 (Stage II), underwent a distal gastrectomy with D2 lymphadenectomy.
  • CY1 was detected during the operation and the final findings was T3N2M0H0P0CY1 (Stage IV).
  • The second case is a man in his 20s with gastric cancer, of which clinical finding was T3N0M0P0M0 (Stage IIIa), underwent a distal gastrectomy with D2 lymphadenectomy.
  • CY1 was detected during the operation and the final findings was T3N2M0H0P0CY1 (Stage IV).
  • A combination gastrectomy with D2 lymphadenectomy and postoperative chemotherapy was considered to be a radical treatment for CY1, Stage IV gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Carcinoembryonic Antigen / blood. Drug Combinations. Gastrectomy. Humans. Male. Neoplasm Staging. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106524.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


41. Aragane H, Suchi K, Shimomura M, Katano T, Yasui H, Kan K: [Severe bone marrow suppression during adjuvant chemotherapy for gastric cancer by S-1 and its possible relationship to dihydropyrimidine dehydrogenase deficiency]. Gan To Kagaku Ryoho; 2010 Jan;37(1):131-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Severe bone marrow suppression during adjuvant chemotherapy for gastric cancer by S-1 and its possible relationship to dihydropyrimidine dehydrogenase deficiency].
  • The patient was a 70-year-old woman, who had undergone total gastrectomy and splenectomy with D2 lymph node dissection, for stage II gastric cancer.
  • We admitted S-1 of 80 mg/day in adjuvant chemotherapy on postoperative day 28.
  • Unfortunately, she died of lung edema and multiple organ failure 28 days after chemotherapy.
  • We measured the mRNA expression level of dihydropyrimidine dehydrogenase (DPD) of the patient's liver by the Dannenberg Tumor Profile method.
  • The expression level of DPD was significantly low, so we suggested that the severe bone marrow suppression might have been caused by the disordered metabolism of 5-FU.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Bone Marrow / drug effects. Dihydropyrimidine Dehydrogenase Deficiency. Oxonic Acid / adverse effects. Stomach Neoplasms / therapy. Tegafur / adverse effects
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Drug Combinations. Female. Gastrectomy. Humans. Liver / enzymology. Lymph Node Excision. Splenectomy

  • Genetic Alliance. consumer health - Dihydropyrimidine Dehydrogenase Deficiency.
  • Genetic Alliance. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087047.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


42. Igarashi Y, Aoki T, Kobayashi K, Tanizaki K, Yamanaka C, Komori T, Matsumoto T, Takachi K, Nishioka K, Uemura Y: [A long-term survival case of liver metastasis of gastric cancer under interdisciplinary therapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2318-20
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survival case of liver metastasis of gastric cancer under interdisciplinary therapy].
  • We report herein a long-term survival case of liver metastasis after distal gastrectomy for gastric cancer.
  • A 72-year-old woman, whom we performed distal gastrectomy with D2 lymph node dissection for type 2 gastric cancer at age 66, was diagnosed as pT2N1M0, stage II.
  • No adjuvant therapy was performed.
  • Six courses of therapy were done, and found cCR in the liver metastasis.
  • A total of 23 courses of therapy were done.
  • She received S-1 plus CDDP, and cCR has been maintained for 6 years and 11 months after gastrectomy (5 years and 4 months after liver metastasis) suggesting that the interdisciplinary therapy was effective.
  • [MeSH-major] Liver Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Catheter Ablation. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Embolization, Therapeutic. Female. Gastrectomy. Humans. Lymph Node Excision. Neoplasm Recurrence, Local. Oxonic Acid / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037408.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


43. Mukai M, Tajima T, Sato S, Ninomiya H, Wakui K, Komatsu N, Tsuchiya K, Nakasaki H, Makuuchi H: Recurrence and 5-FU sensitivity of stage II/III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses. Oncol Rep; 2005 Dec;14(6):1505-10
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence and 5-FU sensitivity of stage II/III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses.
  • The 5-year overall survival (OS) rates for patients without occult neoplastic cells (ONCs) were 43.0% in stage II (n=15), 52.2% in stage III (n=23), and 48.5% for stages II and III combined (n=38).
  • For ONC-positive patients, the 5-year OS rates were 44.4% in stage II (n=7; p=0.88322), 11.3% in stage III (n=30; p=0.0006), and 17.5% for stages II and III combined (n=37; p=0.0019).
  • Unlike the non-recurrence group, the ONC(+) patients with recurrence of stage II/III node-positive gastric cancer are unlikely to respond to treatment with 5-FU + LV and may need combination chemotherapy based on L-OHP and/or CPT-11.
  • [MeSH-major] Fluorouracil / therapeutic use. Lymph Nodes / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Dihydrouracil Dehydrogenase (NADP) / metabolism. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Survival Analysis. Thymidylate Synthase / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273246.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


44. Maeda Y, Sato Y, Yamamoto M, Shomura H, Honnma S, Kohashi S, Shinohara T, Takahashi S, Kondo M, Todo S: [Evaluation of low-dose FP therapy as adjuvant therapy for gastric cancer]. Gan To Kagaku Ryoho; 2005 Mar;32(3):381-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of low-dose FP therapy as adjuvant therapy for gastric cancer].
  • In the present study, we demonstrate the result of low-dose FP treatment as an adjuvant therapy for 30 patients of stage II or more progressive gastric cancer.
  • Patients were excluded if they received less than 80% of the respective doses in a course of treatment by the protocol.
  • This constituted a course of chemotherapy, which was repeated every 4 weeks.
  • The median survival time of the cur C patients was 10 months.
  • These results indicate that low-dose FP therapy is safe and recommendable for cur A and cur B patients.
  • However, other treatment methods such as sequential chemotherapy are needed for cur C gastric cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Gastrectomy. Humans. Injections, Intravenous. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791822.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; 5-FU-CDDP protocol
  •  go-up   go-down


45. Carrato A, Gallego-Plazas J, Guillen-Ponce C: Adjuvant therapy of resected gastric cancer is necessary. Semin Oncol; 2005 Dec;32(6 Suppl 9):S105-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy of resected gastric cancer is necessary.
  • The currently reported 5-year survival rates for patients with resected stage II, IIIA, IIIB, and IV gastric cancer are 34%, 20%, 8%, and 7%, respectively.
  • A subtotal or total gastrectomy with a D1 en bloc dissection of lymphatic tissue is the standard surgical treatment.
  • Several meta-analyses of post-operative adjuvant trials have reported a significant benefit for chemotherapy-treated patients.
  • The 3-year survival and 3-year disease-free survival rates were significantly higher in the adjuvant treatment group, making this regimen the adjuvant standard in the United States.
  • A second trial, the MAGIC trial, also showed improved survival and disease-free survival with epirubicin, cisplatin, and 5-FU (ECF) given every 3 weeks pre- and post-operatively.
  • Other agents in combination with perioperative radiotherapy and surgery are being investigated to treat patients with gastric cancer.
  • New target-oriented agents, as well as tailored therapy based on the molecular profile of both the tumor and the patient, might also contribute to improved results.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Fluorouracil / administration & dosage. Gastrectomy. Humans. Leucovorin / administration & dosage. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399445.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


46. Harada K, Noguchi T, Fujiwara S, Moriyama H, Kitano S, Kawahara K: [Complete response in an elderly patient with advanced gastric cancer treated with TS-1]. Gan To Kagaku Ryoho; 2007 Mar;34(3):427-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete response in an elderly patient with advanced gastric cancer treated with TS-1].
  • He was diagnosed with advanced gastric cancer, T2N1H0P0M0, stage II.
  • Though the curative operation was explained to the patient, he declined it because of complications of advanced age, diabetes and bronchial asthma; chemotherapy was chosen instead.
  • A partial response was observed after the first course, and no cancer cells were confirmed by endoscopic biopsy after the fifth course.
  • Moreover, after the 14th course, CT showed a complete regression of lymph node metastasis, and no cancer cells were confirmed by endoscopic biopsy, for a complete response (CR).
  • From now on, as society grays more and more, it is considered that elderly advanced gastric cancer patients with complications will increase.
  • TS-1 single treatment is considered to be safe and outpatient treatment possible as one of the useful cures.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Diabetes Complications / complications. Drug Administration Schedule. Drug Combinations. Humans. Hypertension / complications. Male. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353636.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


47. Takemura M, Osugi H, Lee S, Taguchi S, Kaneko M, Tanaka Y, Fukuhara K, Fujiwara Y, Nishizawa S, Kinoshita H, Harada S: [A case of synchronous esophageal and gastric cancer successfully treated by combination TS-1/CDDP therapy with irradiation]. Gan To Kagaku Ryoho; 2004 Feb;31(2):251-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of synchronous esophageal and gastric cancer successfully treated by combination TS-1/CDDP therapy with irradiation].
  • We report a case of synchronous esophageal and gastric cancer in a patient with severe liver dysfunction who was treated successfully using TS-1/CDDP therapy combined with irradiation therapy.
  • A 56-year-old man with a chief complaint of dysphagia was diagnosed with thoracic esophageal cancer by endoscopy, and was referred to our hospital.
  • Synchronous esophageal and gastric cancer were diagnosed by endoscopy and barium swallow.
  • The preoperative diagnosis was T3N0M0, Stage II esophageal cancer and T1N0M0, Stage I A gastric cancer, both of which were diagnosed to be resectable.
  • TS-1 (80 mg/day) and CDDP (3 mg/day) therapy was combined with irradiation, 60 Gy given in a T-pattern to the mediastinum.
  • The patient did not suffer any side-effects, and endoscopy performed 44 days after the start of treatment showed that the esophageal lesion was now only a scar.
  • Only a slight elevation of the esophagus was seen by endoscopy 219 days after the start of the therapy.
  • The patient is currently undergoing only TS-1 treatment as an outpatient and is under observation.
  • TS-1 and CDDP therapy combined with radiotherapy appears to be effective in treating thoracic esophageal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Neoplasms, Multiple Primary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Administration, Oral. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Humans. Male. Middle Aged. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Radiotherapy Dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14997762.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


48. Kimura Y, Yasuda T, Fujiwara Y, Takiguchi S, Miyata H, Nagano H, Yano M, Monden M: [Cases of postoperative hepatic metastasis from gastric cancer in which hepatic arterial infusion chemotherapy with 5-FU, adriamycin and cisplatin was performed after TS-1 chemotherapy]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1825-7
Hazardous Substances Data Bank. TITANIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cases of postoperative hepatic metastasis from gastric cancer in which hepatic arterial infusion chemotherapy with 5-FU, adriamycin and cisplatin was performed after TS-1 chemotherapy].
  • The prognosis of patients with hepatic metastasis of gastric cancer is poor, and standard therapies for patients are not established.
  • Here we present two cases of hepatic metastasis from gastric cancer.
  • In both cases, no other organ metastasis except the liver was confirmed, in which hepatic arterial infusion chemotherapy with 5-FU, adriamycin and cisplatin (FAP) were performed because TS-1 chemotherapy was not an effective chemotherapy.
  • Case 1: An 80-year-old man had distal gastrectomy for type 2 gastric cancer (Stage II) in January 2001.
  • After chemotherapy with TS-1 for 5 courses, a hepatic arterial infusion treatment was performed for 7 courses.
  • The effect was PR, but the treatment was canceled because of a catheter obstruction.
  • Case 2: This case was a 73-year-old man who had distal gastrectomy for type 0 IIc gastric cancer (Stage IA) in May 1999.
  • After chemotherapy with TS-1 for 2 courses, a hepatic arterial infusion treatment was performed for 10 courses.
  • The effect was CR, but a peritoneal recurrence was discovered, and a systemic chemotherapy was performed.
  • The hepatic arterial infusion chemotherapy with FAP was effective for gastric cancer patients with liver metastasis because TS-1 chemotherapy was not an effective chemotherapy.
  • It is necessary to consider combined chemotherapy in addition to systemic chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Fluorouracil / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Silicates / therapeutic use. Stomach Neoplasms / pathology. Titanium / therapeutic use

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553728.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Silicates; 12067-57-1 / titanium silicide; 80168379AG / Doxorubicin; D1JT611TNE / Titanium; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; FAP protocol
  •  go-up   go-down


49. Nakane Y, Inoue K, Michiura T, Nakai K, Sato M, Baden T, Okumura S, Yamamichi K: Combined S-1 and cisplatin preoperative chemotherapy for patients with advanced gastric cancer: report of five cases. Hepatogastroenterology; 2004 Jan-Feb;51(55):289-93
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined S-1 and cisplatin preoperative chemotherapy for patients with advanced gastric cancer: report of five cases.
  • BACKGROUND/AIMS: A high response rate with acceptable toxicities is required in the setting of neoadjuvant chemotherapy.
  • Five cases (3 stage IV, 2 stage IIIb) of advanced gastric cancer were successfully treated by neoadjuvant chemotherapy consisting of a combination of S-1 and cisplatin.
  • Surgery was carried out about 3 weeks after chemotherapy.
  • Toxicities, according to the WHO criteria, were very mild and none required treatment.
  • Postoperatively one patient died of aspiration pneumonia unrelated to the chemotherapy.
  • CONCLUSIONS: S-1 plus cisplatin seems safe and effective as neoadjuvant chemotherapy in advanced gastric cancer patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Neoadjuvant Therapy. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery. Tegafur / administration & dosage
  • [MeSH-minor] Drug Combinations. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15011888.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


50. Handa R, Iijima S, Doi T, Oshima K, Hoshi M, Makari Y, Miyake Y, Oshima S, Kato T, Kurokawa E, Kikkawa N: [Three successful cases with CPT-11 + CDDP chemotherapy where S-1 failed to respond to recurrent gastric cancer]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2108-10
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three successful cases with CPT-11 + CDDP chemotherapy where S-1 failed to respond to recurrent gastric cancer].
  • We report three successful cases with irinotecan (CPT-11 60 mg/m2) + cisplatin (CDDP 30mg/m2) chemotherapy (once in 2 weeks) where S-1 failed to respond to recurrent gastric cancer.
  • Case 1: A total gastrectomy and splenectomy were performed for a cardiac gastric cancer (T3, N2, H0, P0, CY0, por 1, Stage IIIB).
  • Case 2: A total gastrectomy, splenectomy and cholecystectomy were performed for a cardiac gastric cancer (T3, N3, H0, P0, CY1, tub1, Stage IV).
  • After the surgery, we treated this patient with S-1 mono-therapy.
  • However, we finished this treatment for abdominal recurrence.
  • Case 3: A distal gastrectomy and cholecystectomy were performed for a pyloric gastric cancer (T2, N1, H0, P0, CY0, tub 2, Stage II).
  • We treated this patient with S-1 + paclitaxel (PTX) chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / therapeutic use. Oxonic Acid / therapeutic use. Salvage Therapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Drug Combinations. Female. Follow-Up Studies. Gastrectomy. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Recurrence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219914.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


51. Ueda Y, Fujimura T, Kinami S, Hirono Y, Yamaguchi A, Naitoh H, Tani T, Kaji M, Yamagishi H, Miwa K, Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC): A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC). Jpn J Clin Oncol; 2006 Aug;36(8):519-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).
  • In this randomized multicenter Phase III study, patients with curatively resected Stage II/IIIA gastric cancer were assigned to postoperative adjuvant therapy with an oral fluoropyrimidine S-1 alone (2 weeks of treatment and 1 week of rest for 6 months, followed by 2 weeks of treatment and 2 weeks of rest for 6 months) or S-1 combined with an oral biological response modifier PSK (the same regimen of S-1 plus daily PSK for 12 months).
  • The main objective was to evaluate the survival benefit and quality of life (QOL) of combined therapy.
  • The primary end points were the time to relapse and the duration of survival after surgery, i.e. the rates of disease-free survival and overall survival at 3 and 5 years.
  • The secondary end points were the relations of survival rates to drug compliance, QOL, adverse events, postoperative complications, relapse status, and the preoperative expression of immune or tumor markers.
  • The sample size was 140 per treatment arm.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Immunologic Factors / administration & dosage. Immunotherapy. Oxonic Acid / administration & dosage. Proteoglycans / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Drug Combinations. Gastrectomy. Humans. Middle Aged. Neoplasm Staging. Quality of Life. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803844.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00216034
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Immunologic Factors; 0 / Proteoglycans; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 66455-27-4 / krestin
  •  go-up   go-down


52. Mayer RJ: Efficacy of neo- and adjuvant treatment modalities in gastrointestinal cancer patients. Swiss Surg; 2001;7(6):239-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of neo- and adjuvant treatment modalities in gastrointestinal cancer patients.
  • Data which have emerged from randomized clinical trials are inconclusive regarding the efficacy of neoadjuvant chemoradiation therapy for patients with esophageal cancer.
  • In 2001, available data appear to support the use of adjuvant chemoradiation therapy following the complete resection of a gastric cancer, adjuvant chemotherapy following the resection of a stage III (and--probably--"high-risk" stage II) colon cancer, and the use of adjuvant (and most likely neoadjuvant) chemoradiation therapy for stages II and III rectal cancer.
  • [MeSH-major] Gastrointestinal Neoplasms / therapy. Neoadjuvant Therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11771440.001).
  • [ISSN] 1023-9332
  • [Journal-full-title] Swiss surgery = Schweizer Chirurgie = Chirurgie suisse = Chirurgia svizzera
  • [ISO-abbreviation] Swiss Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


53. Hayashi Y, Akiyama J, Watanabe M, Nozaki Y, Iwashita R, Nagaoki Y, Sakurai T, Oshima T, Nagata N, Yago Y, Sako A, Kobayakawa M, Tamegai Y, Masaki N, Uemura N, Umeda N: [A case of recurrent gastric cancer with peritoneal dissemination--prolonging life and good QOL by chemotherapy with combined use of paclitaxel]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1861-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent gastric cancer with peritoneal dissemination--prolonging life and good QOL by chemotherapy with combined use of paclitaxel].
  • A 55-year-old man with advanced gastric cancer underwent total gastrectomy (T3N0M0, stage II , por, sig) in the USA.
  • Systemic chemotherapy of paclitaxel combined with 5-FU was performed, and after four cycles, ileus, bilateral hydronephrosis and ascites disappeared.
  • Colostomy was performed and systemic chemotherapy of paclitaxel combined with S-1 was performed.
  • This case suggests that paclitaxel-based chemotherapy is a promising treatment for gastric cancer with peritoneal dissemination.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms / secondary. Quality of Life. Stomach Neoplasms / drug therapy
  • [MeSH-minor] CA-125 Antigen / blood. Carcinoembryonic Antigen / blood. Combined Modality Therapy. Drug Administration Schedule. Fluorouracil / administration & dosage. Gastrectomy. Humans. Male. Middle Aged. Paclitaxel / administration & dosage. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030025.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


54. Matsumoto H, Hirai T, Hirabayashi Y, Murakami H, Higashida M, Kawabe Y, Fuchimoto M, Fujikura H, Hato S, Urakami A, Yamashita K, Tsunoda T: [Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients]. Gan To Kagaku Ryoho; 2007 Jun;34(6):869-73
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients].
  • We studied the pharmacokinetics of 5-FU after S-1 oral administration at the usual dose (80 mg/m2) for adjuvant chemotherapy in 13 advanced gastric cancer patients (Stage II, III), and at a decreased dose (60 mg/m2) for adjuvant or combined chemotherapy in 13 advanced gastric cancer patients.
  • The difference of Cmax and AUC was 3-4 times.
  • It was concluded that we must pay attention to individual differences in the plasma concentration of 5-FU in postoperative gastric cancer patients when S-1 would be administered.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Fluorouracil / pharmacokinetics. Gastrectomy. Oxonic Acid / administration & dosage. Stomach Neoplasms / blood. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Administration, Oral. Aged. Chemotherapy, Adjuvant. Drug Combinations. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565248.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; U3P01618RT / Fluorouracil
  •  go-up   go-down


55. Maruyama M, Nagahama T, Sato E, Maruyama S, Sanada T, Koide A, Ohhinata R, Ebana H: [Study on adjuvant MTX-5-FU intraperitoneal chemotherapy for advanced gastric cancer]. Gan To Kagaku Ryoho; 2008 Nov;35(12):1993-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on adjuvant MTX-5-FU intraperitoneal chemotherapy for advanced gastric cancer].
  • The intraperitoneal administration of anti-cancer drug is a rationale route to adjuvant chemotherapy.
  • We applied adjuvant MTX-5-FU intraperitoneal chemotherapy for 60 advanced gastric cancer cases which had undergone gastrectomy (Stage II 18, Stage III A 19, Stage IIIB 13, and Stage IV 10 cases).
  • A 5-year survival rate of Stage II, III A, IIIB and IV was 66.2%, 60.7%, 46.5% and 18.8%, respectively.
  • Five-year survival rates of both Stage III A and IIIB on this study were likely to be higher than the rates of Stage III A and IIIB of other institutions.
  • The 24 out of 42 cases with the serosal surface exposure of cancer demonstrated a cancer recurrence.
  • Seventy percent (17 cases) of the 24 recurred cases developed a peritoneal recurrence, which means that the intraperitoneal chemotherapy did not touch a pattern of the recurrence of the gastric cancer with the serosal surface exposure.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Infusions, Parenteral. Male. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106501.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


56. Itoh H, Bando E, Kawamura T, Ii T, Takegawa S, Kiriyama M, Dohba S, Kojima Y, Watanabe K: [A case of stage IV gastric carcinoma with lymph nodes metastases of the paraaorta responding markedly to TS-1]. Gan To Kagaku Ryoho; 2002 Dec;29(13):2549-53
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV gastric carcinoma with lymph nodes metastases of the paraaorta responding markedly to TS-1].
  • A 64-year-old man had undergone subtotal gastrectomy with a D2 lymphadenectomy for advanced carcinoma of the stomach with paraaortic lymph nodes metastases 12 months earlier.
  • The histopathological findings revealed a well differentiated adenocarcinoma [type 2 macroscopic findings, SE, INF beta, ly2, v1, N2, M1 (LYM)].
  • An abdominal ultrasonography and a computed tomography (CT) revealed lymph node swelling of the paraaorta.
  • After non-curative operation, he has received adjuvant chemotherapy with TS-1 plus CDDP.
  • At first, 100 mg/day of TS-1 was orally administered for three weeks followed by two drug-free weeks, with CDDP (60 mg/m2/day) infused on day 8.
  • Next, the treatment course consisted of four-week consecutive administration of TS-1 (80 mg/day) followed by two drug-free weeks, with biweekly infusion of CDDP at a dose of 15 mg/m2.
  • The patient is now in a good health and continues to undergo low dose TS-1 plus CDDP chemotherapy as an outpatient.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes / pathology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aorta. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Gastrectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Remission Induction. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12506481.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


57. Ott K, Lordick F: [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]. Chirurg; 2009 Nov;80(11):1028-34
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint].
  • [Transliterated title] Neoadjuvante Therapie im oberen Gastrointestinaltrakt. Magenkarzinom aus chirurgischer Sicht.
  • The prognosis of locally advanced gastric cancer remains poor.
  • It has been shown that multimodal treatment can improve the outcome in comparison to surgery alone.
  • Two randomized studies that have been performed in Europe have shown that peri-operative chemotherapy significantly improves the survival of patients with adenocarcinoma of the stomach and of the gastro-esophageal junction.
  • These results have a profound effect on the treatment of patients presenting with stage II or stage III disease.
  • After neoadjuvant chemotherapy patients should undergo a D-2 lymphadenectomy due to the high probability of lymph node metastasis.
  • Neither mortality nor complication rate are increased after neoadjuvant chemotherapy for gastric cancer.
  • Patients with locally advanced gastric cancer should always be referred to experienced high volume centers, where the findings are discussed in a multidisciplinary tumor board.
  • [MeSH-major] Adenocarcinoma / surgery. Esophagogastric Junction. Neoadjuvant Therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Cooperative Behavior. Disease-Free Survival. Hospitals, University. Humans. Interdisciplinary Communication. Lymph Node Excision. Lymphatic Metastasis. Neoplasm Staging. Patient Care Team. Prognosis. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3719-25 [17704421.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2885-94 [16929515.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):309-15 [16574546.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14 (7):2012-8 [18381939.001]
  • [Cites] Chirurg. 2006 Nov;77(11):971-80 [17066269.001]
  • [Cites] Chirurg. 2007 Sep;78(9):792-801 [17676284.001]
  • [Cites] Gastric Cancer. 2005;8(1):1-5 [15747167.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):1017-25 [19189186.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):1-8 [17592282.001]
  • [Cites] Chirurg. 2006 Mar;77(3):227-35 [16511688.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Radiology. 2006 May;239(2):472-80 [16543584.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5095-102 [17785563.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):303-8 [10077040.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2307-15 [12796400.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):808-16 [15492562.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):453-62 [18669424.001]
  • [Cites] Gastric Cancer. 2008;11(1):1-9 [18373171.001]
  • [Cites] Lancet Oncol. 2006 Aug;7(8):644-51 [16887481.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] J Am Coll Surg. 2007 Oct;205(4):593-601 [17903735.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Chirurg. 1999 May;70(5):520-9 [10412596.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 19756431.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


58. Kato K, Koide A, Oobu M, Hasegawa K, Maruyama S, Takashima I, Nagahama T, Maruyama M, Ebuchi M: [A case of gastric cancer with peritoneal dissemination which shows a remarkable efficacy by a weekly administration of paclitaxel intraperitoneally]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1852-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with peritoneal dissemination which shows a remarkable efficacy by a weekly administration of paclitaxel intraperitoneally].
  • We treated a 65-year-old female with gastric cancer who underwent peritoneal dissemination after 6 successive weeks of paclitaxel intraperitoneal therapy (90 mg/body), and obtained a disappearance of ascites and a reduction of the primary carcinoma.
  • Operative findings: U ant, type 5, 26x20 mm, por, T2, n1(+), H0, P0, CY0, M0, stage II, and grade 2.
  • A weekly paclitaxel intraperitoneal therapy could be a useful for both peritoneal dissemination and the primary carcinoma of advanced gastric carcinoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Neoplasm Seeding. Paclitaxel / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Drug Administration Schedule. Female. Humans. Injections, Intraperitoneal. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553737.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


59. Lu Y, Liu C, Zhang R, Li H, Lu P, Jin F, Xu H, Wang S, Chen J: Prognostic significance of subclassification of pT2 gastric cancer: a retrospective study of 847 patients. Surg Oncol; 2008 Dec;17(4):317-22
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of subclassification of pT2 gastric cancer: a retrospective study of 847 patients.
  • PURPOSE: To investigate the prognostic significance of subclassification of pT2 gastric cancers according to the nodal status.
  • METHODS: Clinicopathological characteristics and prognostic outcomes of 847 gastric cancer patients who received a gastrectomy between 1985 and 2003 were retrospectively evaluated based on the subclassification of pT2 stage (i.e. pT2a and pT2b).
  • RESULTS: Of the patients, 244 and 603 had pT2a and pT2b stage cancers, respectively.
  • The prognosis was significantly better in patients with pT2a cancers than in patients with pT2b cancers at pN0, pN1 and pN2 (P=0.036, 0.021, and 0.019 respectively), but not pN3 stages (P=0.775).
  • Multivariate analysis identified age, tumor location, pT stages, pN stages, and adjuvant chemotherapy as independent prognostic factors for pT2 gastric cancers.
  • The survival rates were similar between pT2aN1 (stage II) and pT2bN0 (stage IB) cancers (P=0.604), and between pT2aN2 (stage IIIA) and pT2bN1 (stage II) cancers (P=0.936).
  • CONCLUSIONS: Subclassification of pT2 gastric cancers into pT2a or pT2b is of prominent prognostic significance, and thus it is recommended that the current stage grouping conventions include subclassification of pT2, in order to more accurately predict the prognosis of patients.
  • [MeSH-major] Neoplasm Staging / methods. Stomach Neoplasms / classification. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586486.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


60. Nakamura R, Saikawa Y, Wada N, Yoshida M, Kubota T, Kumai K, Kitajima M: Retrospective analysis of prognosis for scirrhous-type gastric cancer: one institution's experience. Int J Clin Oncol; 2007 Aug;12(4):291-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of prognosis for scirrhous-type gastric cancer: one institution's experience.
  • BACKGROUND: Scirrhous gastric cancer is biologically aggressive, and the prognosis is poor even with curative surgery.
  • We compared outcomes with different therapies in order to identify prognostic factors.
  • METHODS: Records for 83 patients, who were treated between 1991 and 2004, were evaluated for survival and stage, treatment, and clinicopathological factors.
  • RESULTS: Cumulative 5-year overall survival was 10.2% for all 83 patients, including 27 (32.5%) patients with stage II/III disease and 56 (67.4%) with stage IV disease.
  • The 5-year overall survival rate and median survival time for patients with stage II/III disease after curative surgery were 24.3% and 1150 days.
  • For patients with stage IV disease, 2-year and 5-year survival rates after initial surgery were 13.7% and 0% and median survival was 250 days.
  • In contrast, preoperative chemotherapy for advanced, unresectable disease produced 2-year and 3-year overall survival rates of 53.6% and 26.8% and medican survival was 910 days.
  • CONCLUSION: Aggressive surgery alone does not seem to improve outcome, but preoperative chemotherapy might be beneficial and should be investigated further.
  • [MeSH-major] Adenocarcinoma, Scirrhous / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1997 Apr-May;4(3):209-14 [9142381.001]
  • [Cites] J Surg Oncol. 1995 Feb;58(2):112-7 [7844980.001]
  • [Cites] Surg Gynecol Obstet. 1992 Jul;175(1):13-6 [1621194.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):381-6 [12579276.001]
  • [Cites] Surgery. 1989 Oct;106(4):758-62; discussion 762-3 [2552599.001]
  • [Cites] J Surg Oncol. 1997 Jul;65(3):194-200 [9236929.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Dig Dis Sci. 1992 May;37(5):757-63 [1563320.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):314-8 [15783058.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] Am J Surg. 2004 Sep;188(3):327-32 [15450843.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:40-4 [12775019.001]
  • [Cites] Intern Med. 1996 Dec;35(12):930-6 [9030989.001]
  • (PMID = 17701009.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. Sasako M, Saka M, Fukagawa T, Katai H, Sano T: [Adjuvant chemotherapy using S-1 for curatively resected gastric cancer-the nationwide clinical trial]. Gan To Kagaku Ryoho; 2006 Jun;33 Suppl 1:110-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy using S-1 for curatively resected gastric cancer-the nationwide clinical trial].
  • Actually there has been no established adjuvant therapy for curable gastric cancer.
  • A large scale clinical trial on adjuvant chemotherapy for gastric cancer using S-1 (ACTS-GC) started in 2001.
  • The target population was Stage II, IIIA, IIIB, and the expected hazard ratio was less than 0.70.
  • Thus it was proven that we should carry out a pivotal study instead of making meta-analysis in the field of gastric cancer.
  • If the results are negative, the use of adjuvant chemotherapy in practice and in social insurance might be restricted.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Oxonic Acid / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials as Topic. Drug Administration Schedule. Drug Combinations. Humans. Meta-Analysis as Topic. Neoplasm Staging. Registries. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16897984.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  • [Number-of-references] 3
  •  go-up   go-down


62. Kim R, Yoshida K, Toge T: [Current status and future perspectives on chemotherapy in patients with gastric cancer: can the clinical data from Japan lead to a standard international therapy?]. Nihon Geka Gakkai Zasshi; 2001 Oct;102(10):770-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current status and future perspectives on chemotherapy in patients with gastric cancer: can the clinical data from Japan lead to a standard international therapy?].
  • From a meta-analysis of clinical studies in Japan and the West, although no survival benefit for stage I gastric cancer was observed in patients who received postoperative adjuvant chemotherapy, the survival benefit for patients with stage II and III disease was small and marginal effect, respectively, since the odds ratios were between 0.80 and 0.82 with a 95% confidence interval of less than 1.0.
  • Anticancer drugs used for combination therapy included mitomycin C, anthracyclines, alkylating agents, and 5-fluorouracil.
  • Increased long-term survival and the prevention of peritoneal recurrence were found in some patients who received combination therapy with mitomycin C, 5-fluorouracil, and nonspecific immunomodulators such as PSK and OK-432.
  • Regarding chemotherapy for advanced and recurrent cases, administration of biochemical modulators such as low-dose FP and the new dehydropyrimidine dehydrogenase inhibitory fluoropyrimidine agent S 1 resulted in increased response rates, improved quality of life, and prolongation of survival.
  • The development of rigorous trials and personalized chemotherapy with molecular targeting are needed to achieve further survival benefit for patients with gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / standards. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11681004.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 20
  •  go-up   go-down


63. Nakajo A, Natsugoe S, Hokita S, Ishigami S, Takatori H, Arigami T, Uenosono Y, Aridome K, Aikou T: Successful treatment of advanced gastric cancer by surgical resection following combination chemotherapy with oral S-1 and biweekly paclitaxel. Gastric Cancer; 2007;10(1):58-62
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of advanced gastric cancer by surgical resection following combination chemotherapy with oral S-1 and biweekly paclitaxel.
  • We report on the successful treatment of advanced gastric cancer by surgical resection following neoadjuvant chemotherapy.
  • A 67-year-old man was referred to our hospital with a diagnosis of pancreatic cancer.
  • Meticulous examination, however, revealed the presence of gastric cancer with ascites and large lymph node metastasis adjacent to the pancreas.
  • We selected combination chemotherapy with oral S-1 and biweekly paclitaxel.
  • The patient underwent distal gastrectomy with D2 lymph node dissection.
  • Histological examination revealed that the cancer cells were still present in part, but no lymph node metastases were found.
  • The tumor was pathologically diagnosed as pT2, pN0, P0, M0, CY0, and p-stage II.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Combinations. Gastrectomy. Humans. Male. Neoadjuvant Therapy. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Drugs. 1996 Feb;7(2):137-49 [8740718.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:50-7 [12775021.001]
  • [Cites] Oncology. 2001;61(1):16-22 [11474243.001]
  • [Cites] Gastric Cancer. 2004;7(2):128-33 [15224201.001]
  • [Cites] Int J Clin Oncol. 2005 Feb;10(1):40-4 [15729600.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):342-5 [15333687.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:45-9 [12775020.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Int J Clin Oncol. 2002 Oct;7(5):326-9 [12402069.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(3):205-11 [8996521.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2328-33 [14556924.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] Cell. 1981 Jan;23(1):61-71 [6111398.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jun;57(6):736-40 [16163539.001]
  • (PMID = 17334720.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


64. Cui Q, Dong X, Wang D, Hao X, Wang J, Li Q, Kong D, Liu N: Diagnosis and treatment of primary gastric non-Hodgkin's lymphoma: analysis of 157 patients. Zhonghua Yu Fang Yi Xue Za Zhi; 2002 Dec;36(7):502-4
Genetic Alliance. consumer health - Gastric Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of primary gastric non-Hodgkin's lymphoma: analysis of 157 patients.
  • OBJECTIVE: To seek the optimum treatment for patients with primary gastric non-Hodgkin's lymphoma and factors associated with prognosis.
  • METHODS: A retrospective study was conducted on 157 primary gastric non-Hodgkin's lymphoma patients who had received operation for 45 years.
  • RESULTS: The X-ray diagnosis rate was 39.4% before operation.
  • The diagnosis rate by gastroscopy was 52.7%.
  • Among the 157 patients, 32 belonged to stage I(E), 40 stage II(E), 29 stage III(E), and 56 stage IV(E).
  • All of the patients were received chemotherapy or radiation.
  • CONCLUSIONS: The 3-, 5-year survival rates in stage I(E) and stage II(E) were 2 to 5 times higher than those in stage III(E) and IV(E) (P < 0.01).
  • The 3-, 5-year survival rates of primary gastric non-Hodgkin's lymphoma were 60.2% (65/108) and 50.0% (52/104) respectively.
  • The prognosis was better than the 5-year survival rate of gastric cancer patients with D(2) lymphodenectomy (33.3%).
  • Early diagnosis and treatment are effective to prevent complications, enhance quality of patient's life, and prolong the survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12411154.001).
  • [ISSN] 0253-9624
  • [Journal-full-title] Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
  • [ISO-abbreviation] Zhonghua Yu Fang Yi Xue Za Zhi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


65. Liang Z, Hu WD, Gu ZD, Xiong HC, Chen KN: [Evaluation of transhiatus esophagectomy for patients with esophageal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Sep;11(5):451-3
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of transhiatus esophagectomy for patients with esophageal cancer].
  • OBJECTIVE: To evaluate the transhiatus esophagectomy for patients with esophageal cancer.
  • METHODS: Clinicopathological data of 46 patients with esophageal cancer undergone transhiatus esophagectomy by single surgeon team from May 2000 to July 2007 were analyzed retrospectively.
  • RESULTS: These 46 patients included 44 esophageal squamous cell carcinomas,1 esophageal adenocarcinoma and 1 esophageal carcinoid.
  • All the patients were classified according to UICC TNM stage classification: 3 cases as stage 0, 6 cases as stage I, 17 cases as stage II a, 2 cases as stage II b, 16 cases as stage III.
  • Six patients received preoperative chemotherapy and pathological complete response was seen in 2 cases.
  • Reconstruction with stomach was performed in 42 cases and with colon interposition in 4 cases.All the tumors were resected, and there was no perioperative death.
  • CONCLUSION: Transhiatus esophagectomy is an ideal choice in surgical treatment for patients with esophageal cancer, especially for the ones of aged, poor cardiac or pulmonary function, who can not afford the thoracotomy.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803048.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


66. Yang H, Wu AW, Li ZY, Bu ZD, Zhang LH, Wu XJ, Zong XL, Li SX, Shan F, Yang Y, Ji JF: [Surgical treatment results and prognostic analysis of 514 cases with gastroesophageal junction carcinoma]. Zhonghua Wai Ke Za Zhi; 2010 Sep 1;48(17):1289-94
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment results and prognostic analysis of 514 cases with gastroesophageal junction carcinoma].
  • OBJECTIVE: To clarify the important clinicopathological and therapeutical factors affecting the prognosis of patients with gastroesophageal junction carcinoma.
  • METHODS: Data of 514 cases with gastroesophageal junction carcinoma who underwent surgical treatment from September 1995 to January 2007 was retrospectively analyzed.
  • Gross type, TNM classification, histological type, vascular invasion and extent of surgical resection affected patients' survival remarkably.
  • For stage II and III tumors, patients with neoadjuvant chemotherapy had better prognosis than those without (P < 0.05).
  • CONCLUSIONS: TNM classification and vascular invasion are independent prognostic factors for gastroesophageal junction carcinoma.
  • Neoadjuvant chemotherapy may improve prognosis of the patients with stage II and III tumors.
  • [MeSH-major] Carcinoma / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21092605.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


67. Ebisui C, Ohkubo K, Akitake H, Ohtsuka M, Yamanaka C, Maekawa T, Yoshioka S, Hama N, Kashiwazaki M, Taniguchi M, Tsujie M, Konishi M, Fujimoto T: [A case of left inguinal malignant lymphoma occurred after radical operation for gastric cancer and gastrointestinal stromal tumor]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2130-2
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of left inguinal malignant lymphoma occurred after radical operation for gastric cancer and gastrointestinal stromal tumor].
  • In March 2005, a 70-year-old male patient underwent distal gastrectomy with D2 lymph node dissection for type 3 gastric cancer located in the lower-third of the stomach, and partial gastrectomy for submucosal tumor located in the upper- third of the stomach.
  • A post operative pathological finding of cancer was T2N0P0H0M0 (f-Stage II) and that of submucosal tumor was gastrointestinal stromal tumor.
  • Although the adjuvant chemotherapy of S-1 was administered, it was discontinued because of cerebral infarction.
  • Forty months after the operation, CT scan revealed a left inguinal lymph node swelling and recurrence of gastric cancer was doubted.
  • [MeSH-major] Gastrointestinal Stromal Tumors / surgery. Lymphoma, Follicular / pathology. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037346.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


68. Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK: Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma. Eur J Surg Oncol; 2007 Sep;33(7):843-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
  • AIM: This study aimed to evaluate the efficacy and safety of 5-fluorouracil (5-FU), doxorubicin and mitomycin-C (FAM) adjuvant chemotherapy in patients who had undergone curative resection of gastric carcinoma.
  • METHODS: From Nov 1999 to Jan 2002, 291 consecutive patients with stage IB-IIIB gastric adenocarcinoma were given FAM adjuvant chemotherapy.
  • Chemotherapy comprised intravenous 5-FU 600 mg/m(2) (days 1, 8, 29 and 36), doxorubicin 30 mg/m(2) (days 1 and 29) and mitomycin-C 10 mg/m(2) (day 1), every 8 weeks for 6 months.
  • RESULTS: The median follow-up time was 60.6 months, 92 patients died, and 93 patients had recurrent disease.
  • The 5-year overall survival (OS) rates were 85.9% for stage IB, 72.1% for stage II, 58.0% for stage IIIA, and 48.2% for stage IIIB (p=0.002).
  • The 5-year relapse-free survival (RFS) rates were 85.2% for stage IB, 71.2% for stage II, 53.3% for stage IIIA, and 39.2% for stage IIIB (p<0.001).
  • A total of 769 cycles of chemotherapy were delivered, and 15 patients experienced grade 3 or higher leukopenia.
  • CONCLUSIONS: Adjuvant chemotherapy with FAM for 6 months for gastric carcinoma indicated comparable RFS and OS with an acceptable toxicity profile.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy / methods. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Incidence. Korea / epidemiology. Male. Middle Aged. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Retrospective Studies. Survival Rate / trends. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207959.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; FAM protocol
  •  go-up   go-down


69. Ito S, Kodera Y, Mochizuki Y, Kojima T, Nakanishi H, Yamamura Y: Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR. World J Surg; 2010 Sep;34(9):2083-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR.
  • BACKGROUND: We have previously reported the molecular detection of peritoneal micrometastases in patients with gastric cancer by quantifying carcinoembryonic antigen (CEA) mRNA in the peritoneal washes.
  • Patients with CEA mRNA exceeding a cutoff value have a significant risk for developing peritoneal carcinomatosis, but optimal treatment for this population remains unknown.
  • METHODS: CEA mRNA (+) patients with gastric cancer were treated postoperatively with S-1 monotherapy.
  • Overall survival, the primary endpoint of this phase II trial, was compared with the historical control, which is comprised of CEA mRNA (+) patients who were not given postoperative chemotherapy.
  • RESULTS: A total of 32 patients with CEA mRNA (+) gastric cancer were enrolled.
  • CONCLUSIONS: S-1 monotherapy, which significantly reduced risk for recurrence in stage II/III gastric carcinoma in another phase III trial, seems not to be as effective in eradicating free cancer cells in the abdominal cavity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Oxonic Acid / administration & dosage. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Tegafur / administration & dosage
  • [MeSH-minor] Carcinoembryonic Antigen / analysis. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Combinations. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Peritoneal Lavage. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2011 Feb;35(2):468-9; author reply 470-1 [20857104.001]
  • [Cites] J Am Coll Surg. 2006 Feb;202(2):231-6 [16427547.001]
  • [Cites] Hepatogastroenterology. 2007 Apr-May;54(75):960-3 [17591103.001]
  • [Cites] Gastric Cancer. 2008;11(4):206-13 [19132482.001]
  • [Cites] Gastric Cancer. 2006;9(4):308-14 [17235634.001]
  • [Cites] Ann Surg Oncol. 2007 May;14 (5):1694-702 [17294072.001]
  • [Cites] Jpn J Cancer Res. 1997 Jul;88(7):687-92 [9310142.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):411-7 [11008202.001]
  • [Cites] Clin Cancer Res. 1997 May;3(5):653-9 [9815733.001]
  • [Cites] Langenbecks Arch Surg. 2005 Sep;390(5):430-41 [15991048.001]
  • [Cites] Gastric Cancer. 2004;7(2):104-9 [15224197.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):637-44 [16077911.001]
  • [Cites] Jpn J Clin Oncol. 2005 Nov;35(11):672-5 [16275676.001]
  • [Cites] Br J Surg. 1990 Apr;77(4):436-9 [2340396.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Lancet Oncol. 2003 May;4(5):277-83 [12732164.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):986-92 [16205696.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S32-6 [10357556.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):581-9 [11520161.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):361-8 [16428473.001]
  • [Cites] Eur J Surg Oncol. 2009 Nov;35(11):1158-63 [19328643.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):429-33 [9699538.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2609-16 [18451223.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):499-506 [11923605.001]
  • (PMID = 20379713.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


70. Mlkvý P: Multimodal therapy of gastric cancer. Dig Dis; 2010;28(4-5):615-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal therapy of gastric cancer.
  • Adenocarcinoma of the stomach is the 2nd most common cancer worldwide.
  • The 5-year survival rates after curative surgical resection decline from 60-90% in stage I, to 30-50% in stage II and finally drop to only to 10-25% for patients in stage III of this disease.
  • Surgical treatment is the only therapeutic modality that has a potentially curative effect.
  • According to certain criteria, early gastric cancer limited to the mucosa or submucosa is indicated for endoscopic mucosal resection.
  • In advanced gastric cancer with surgical approach, the questions of type of resection, extent of lymph node dissection and indication for splenectomy do arise.
  • Chemotherapy is the treatment of choice in stage IV for unresectable disease.
  • According to numerous randomized controlled trials, adjuvant chemotherapy versus chemoradiotherapy have been accepted for stages Ib-IIIb of this disease.
  • Combination chemotherapy seems to be more effective than monotherapy.
  • Neoadjuvant chemotherapy is administered with the aim to downstage a locally advanced tumor prior to attempting curative resection.
  • New therapeutic possibilities include agents like angiogenesis inhibitors, human epidermal growth factor receptor family inhibitors and inhibitors of small molecules (tyrosine kinase inhibitors).
  • Survival rates in resectable gastric cancer are influenced mainly by the depth of invasion through the gastric wall and by the presence or absence of regional lymph node involvement.
  • [MeSH-major] Stomach Neoplasms / therapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21088412.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


71. Garrido M, Bustos M, Orellana E, Madrid J, Galindo H, Sánchez C, Pimentel F, Guzmán S, Ibáñez L, Butte JM, Alvarez M, Besa P: [Postoperative radio-chemotherapy in locally advanced gastric cancer]. Rev Med Chil; 2008 Jul;136(7):844-50
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative radio-chemotherapy in locally advanced gastric cancer].
  • [Transliterated title] Radio-quimioterapia postoperatoria en cáncer gástrico localmente avanzado.
  • BACKGROUND: Overall 5 years survival for surgically excised gastric cancer is 30%.
  • Adjuvant treatment may improve the surgical results.
  • AIM: To assess treatment results and toxicity in patients with surgically excised gastric cancer, treated with adjuvant radiotherapy and concomitant continuous 5-Fluorouracil (5-FU).
  • MATERIAL AND METHODS: Forty one patients aged 32 to 73 years (29 males) with stage II-IVA gastric cancer, subjected to a total or subtotal gastrectomy and D2 nodal dissection between 1997 to 2006, were studied.
  • They received adjuvant radiotherapy to the gastric bed and draining nodes in a total dose of 50.4 Gy in 28 fractions and chemotherapy with continuous infusion 5-FU, 200 mg/m(2)/day.
  • RESULTS: Eighteen patients were in stage II, 10 in stage IIIA, nine in stage IIIB and four in stage IVA.
  • Radiotherapy was associated with grade 1-2 toxicity and treatment was completed without interruptions in all patients.
  • Chemotherapy was delayed temporarily in 3 patients.
  • CONCLUSIONS: Adjuvant radio-chemotherapy improved overall survival in gastric cancer, compared to historical controls subjected only to surgical treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Postoperative Care. Radiation Dosage. Radiotherapy, Adjuvant. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949159.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


72. Tsujinaka T, Fujitani K, Hirao M, Kurokawa Y: Current status of chemoradiotherapy for gastric cancer in Japan. Int J Clin Oncol; 2008 Apr;13(2):117-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of chemoradiotherapy for gastric cancer in Japan.
  • Chemoradiotherapy (CRT) is the latest modality to be explored as a treatment for gastric cancer.
  • Advances have been made in the United States with CRT as preoperative or postoperative adjuvant treatment.
  • D2 is standard in Japan and D2 gastrectomy plus postoperative adjuvant chemotherapy with S-1 is currently standard for stage II and III cancer.
  • Predominant recurrence patterns associated with these advanced disease stages are peritoneal dissemination and hematogenous metastasis.
  • The response to and safety of CRT for gastric cancer, in combination with various chemotherapeutic agents, are currently being studied in patients with unresectable or recurrent disease.
  • In the near future, an examination will be made to ascertain whether neoadjuvant CRT in combination with extensive surgery has survival benefits in the treatment of locally advanced disease.
  • Prior to this, a phase I/II study should be conducted in patients with unresectable or recurrent disease.
  • [MeSH-major] Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Gastrectomy. Humans. Japan. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):309-15 [16574546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1279-85 [16099596.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:99-105 [16897982.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Dec;15(6):1431-3 [3198440.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1237-44 [15718321.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2774-80 [15254045.001]
  • [Cites] Lancet. 1969 Oct 25;2(7626):865-7 [4186452.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Cancer J. 2007 May-Jun;13(3):168-74 [17620766.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3953-8 [16921048.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 18463954.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


73. Lee J, Jeong CK, Hong SP, Chong SY, Oh D, Hwang SG, Ahn DH, Kim S, Han JH, Kim NK: [Clinical significance of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in Korean patients with gastric cancer]. Korean J Gastroenterol; 2005 Jul;46(1):32-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in Korean patients with gastric cancer].
  • TS enhancer region (TSER) polymorphism has been associated with the efficacy of 5-FU-based chemotherapy in colon cancer.
  • The aim of this study was to determine the clinical value of TSER and MTHFR polymorphism in gastric cancer.
  • METHODS: From October, 1995 to February, 2002, 40 gastric cancer patients underwent operation and 25 patients among those patients have received postoperative 5-FU-based chemotherapy (5-FU (+) group).
  • RESULTS: We observed a longer survival in stage II than stage III of the patients (p=0.0037).
  • However, the TSER and MTHFR C677T polymorphisms were not associated with better survival of gastric cancer patients as well as combined TSER and MTHFR genotypes with 5-FU chemotherapy.
  • CONCLUSIONS: The TSER and MTHFR genotypes are not effective markers for tumor sensitivity to 5-FU-based chemotherapy in Korean gastric cancer patients after curative resection.
  • These results may suggest further large-scale study about TSER and MTHFR polymorphism for the prediction of efficacy of 5-FU-based chemotherapy in gastric cancer in Korea.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic. Stomach Neoplasms / drug therapy. Thymidylate Synthase / genetics
  • [MeSH-minor] Aged. Drug Screening Assays, Antitumor. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030402.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


74. Zhao L, Li XY, Bai CM, Chen SC: [Post-operative adjuvant treatment with oxaliplatin, fluorouracil, and leucovorin for local advanced gastric cancer]. Zhonghua Yi Xue Za Zhi; 2008 May 13;88(18):1264-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Post-operative adjuvant treatment with oxaliplatin, fluorouracil, and leucovorin for local advanced gastric cancer].
  • OBJECTIVE: To evaluate the toxicity and efficacy of combination regimen with oxaliplatin plus fluorouracil and leucovorin(FOLFOX) as post-operative adjuvant chemotherapy in local advanced gastric cancer.
  • METHODS: Twenty-five gastric cancer patients, 2 at the stage II, 17 at the stage III, and 6 at the stage IV received the FOLFOX regimen after surgery: intravenous infusion of oxaliplatin 85 mg/m2 for 2 h on day 1, intravenous infusion of leucovorin 200 mg/m2 for 2 h on days 1-2, and intravenous bolus injection of 5-fluorouracil (5-FU) 400 mg/m2 on days 1-2, and continuous infusion of 5-FU 600 mg/m2 for 22 h on days 1-2; and this regimen was repeated every 2 weeks.
  • RESULTS: The median disease free survival time and overall survival time were 26.0 months and 38.0 months respectively.
  • CONCLUSION: The post-operative adjuvant chemotherapy of FOLFOX regimen has expectable efficacy in treatment of gastric cancer with light and well tolerable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18844100.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


75. Lin XG, Huang KH, Xie DR, Liu TH: [Postoperative abdominal endogenic field hyperthermia combined with FOLFOX regimen in the treatment of 68 cases of advanced gastric cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct;27(10):1501-3
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative abdominal endogenic field hyperthermia combined with FOLFOX regimen in the treatment of 68 cases of advanced gastric cancer].
  • OBJECTIVE: To assess the therapeutic efficacy and adverse effects of endogenetic field hyperthermia (EFH) in combination with L-OHP /LV / 5-FU in the treatment of advanced gastric cancer.
  • METHODS: This study included 147 surgical patients with stage II-IV gastric cancer, who received postoperative chemotherapy with FOLFOX (L-OHP 85 mg /m square, 3 h intravenous infusion, followed by infusion of LV at 200 mg /m square in 2 h, intravenous injection of 5-Fu at 400 mg /m square, and intravenous infusion of 5-FU at 3000 mg /m square in 48 h).
  • Eight treatment cycles (each lasting for 14 days) were administered.
  • In 68 cases randomly selected from the cohort, EFH was performed on the first and third days (treatment group), but not in the other 79 cases (control group).
  • RESULTS: The response rate was 68.4% in the treatment group and 36.4% in the control group, showing significant difference between them (P<0.05).
  • The 1-year survival rate was 88.2% in the treatment group, similar to the rate of 81.0% in the control group (P< 0.05), but the 3, 5-year survival rates in treatment group (67.6% and 30.9%) was significantly higher than those in the control group (47.6% and 15.4%, P<0.05).
  • CONCLUSION: EFH combined with the chemotherapeutic regimen FOLFOX might improve the therapeutic effect of stage II-IV gastric cancer without obviously increasing the adverse effects.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hyperthermia, Induced. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Middle Aged. Organoplatinum Compounds / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17959524.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


76. Perrone G, Ruffini PA, Catalano V, Spino C, Santini D, Muretto P, Spoto C, Zingaretti C, Sisti V, Alessandroni P, Giordani P, Cicetti A, D'Emidio S, Morini S, Ruzzo A, Magnani M, Tonini G, Rabitti C, Graziano F: Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer; 2008 Sep;44(13):1875-82
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer.
  • We investigated the clinical significance of tumour-infiltrating FOXP3-positive regulatory T cells (Tregs) in radically resected (R0) gastric cancer.
  • From a single-institution database, tumors of 110 patients who underwent R0 resection for stage II-III disease were studied for FOXP3-positive Tregs by immunohistochemistry.
  • Tregs were significantly higher in gastric carcinomas than in normal tissue (P = 0.0001).
  • Multivariate analysis showed association between adverse relapse-free survival and grading 3, stage III, VELIPI and Tregs count >or=6 (P = 0.02).
  • Adverse overall survival was associated with grading 3, stage III, VELIPI and Tregs count >or=6 (P = 0.006).
  • FOXP3-positive Tregs may be a novel marker for identifying high-risk gastric cancer patients.
  • Present findings deserve additional investigation as Tregs may also represent an innovative therapeutic target.
  • [MeSH-major] Adenocarcinoma / metabolism. Forkhead Transcription Factors / metabolism. Stomach Neoplasms / metabolism. T-Lymphocytes, Regulatory / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Gastrectomy / mortality. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / surgery. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18617393.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


77. Peng CW, Li Y, Yang GL, Xiong B, Feng MH, Cheng FL: Postoperative recurrence in gastric cancer: analysis of 59 cases. Hepatogastroenterology; 2010 May-Jun;57(99-100):663-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative recurrence in gastric cancer: analysis of 59 cases.
  • BACKGROUND/AIMS: Gastric cancer (GC) is the leading cause of death in China.
  • Although surgery based comprehensive treatment is the best approach to improve survival, postoperative recurrence is a major problem.
  • This study was aimed to find out the relationship of cancer recurrence with major clinico-pathological factors, with special attention focused on time of recurrence.
  • Time of recurrence, the relationship between clinical stages and time of recurrence, and between number of adjuvant chemotherapy cycles and time of recurrence were evaluated.
  • Median time to recurrence was 7 months.
  • The differences in time of recurrence among stage I, stage II, stage III and stage IV were statistically not significant (p > 0.05, Kruskal-Wallis Test).
  • There were significant differences among different adjuvant chemotherapy cycles for time to recurrence (p = 0.014, Kruskal-Wallis Test).
  • Adjuvant chemotherapy could prolong recurrence-free survival.
  • [MeSH-major] Neoplasm Recurrence, Local / epidemiology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698246.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


78. Katayanagi S, Arai K, Iwasaki Y, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H: [A case of liver metastases from gastric cancer successfully treated with induced hypertensive chemotherapy]. Gan To Kagaku Ryoho; 2003 Oct;30(11):1722-5
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of liver metastases from gastric cancer successfully treated with induced hypertensive chemotherapy].
  • We report a 77-year-old patient with gastric cancer who has survived 5 years after multidisciplinary treatment for both liver and brain recurrences.
  • He underwent a D2 distal gastrectomy for macroscopically type 2 cancer at the lower third of the stomach on May 1997.
  • The histopathological findings were as follows: O-IIc (SM2), poorly differentiated adenocarcinoma, pN2, ly2, v2, stage II.
  • He received both hepatectomy and prophylactic hepatic arterial infusion of mitomycin C with induced hypertensive chemotherapy (IHC), a drug delivery system using the difference in blood flow between normal and tumor vessels by intravenously injected angiotensin-II.
  • We consider multidisciplinary treatment including complete surgical resection as effective, even for recurrent or highly malignant gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Pressure / drug effects. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Angiotensin II / administration & dosage. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Gastrectomy. Hepatectomy. Hepatic Artery. Humans. Injections, Intra-Arterial. Male. Mitomycin / administration & dosage. Proteoglycans / administration & dosage. Radiosurgery. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14619503.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Proteoglycans; 0 / UFT(R) drug; 11128-99-7 / Angiotensin II; 1548R74NSZ / Tegafur; 50SG953SK6 / Mitomycin; 56HH86ZVCT / Uracil; 66455-27-4 / krestin
  •  go-up   go-down


79. Sato A, Nakamachi M, Imataka H, Hamada K: [Clinical development of oral chemotherapeutic agents for advanced gastric cancer]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1192-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical development of oral chemotherapeutic agents for advanced gastric cancer].
  • 5-fluorouracil (5-FU) has been the mainstay of systemic therapy since its initial development 50 years ago for gastrointestinal cancer.
  • In the SPIRITS trial, S-1+CDDP combined chemotherapy showed significant statistical superiority to S-1 monotherapy.
  • On the basis of these results, S-1+CDDP combination therapy was adopted as the standard cancer chemotherapy regimen for inoperable and recurrent gastric cancer.
  • The ACTS-GC trial suggested that adjuvant chemotherapy with S-1 should be adopted as the standard treatment for stage II/III gastric cancer after curative D2 gastric dissection.
  • This manuscript describes the clinical development of oral fluoropyrimidines (S-1, capecitabine) and their modulators for gastric cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647697.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


80. Kim JP, Lee JH, Yu HJ, Yang HK: Result of 11,946 gastric cancer treatment with immunochemosurgery. Gan To Kagaku Ryoho; 2000 May;27 Suppl 2:206-14
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Result of 11,946 gastric cancer treatment with immunochemosurgery.
  • Although the therapeutic results of gastric cancer have markedly improved, it still remains the most common of cancer deaths in Korea.
  • Annually more than 700, and all together 11,946, gastric cancer patients were surgically treated from 1970 to 1998 at Seoul National University Hospital.
  • Stage III gastric cancer is already a systemic disease, Radical surgery alone cannot cure the patient, and about 35% recurred within 2-3 years.
  • To improve the prognosis of advanced gastric cancer, systemic treatment such as immunotherapy and chemotherapy is required in the early postoperative period to kill the micrometastatic or remaining cancer cells after curative resection.
  • The clinicopathologic variables used for evaluating prognostic values were classified into patient, -tumor- and treatment-related factors.
  • The prognostic significance of treatment modality was evaluated in stage III gastric cancer.
  • Radical lymph node dissection was found to produce survival gains in patients with stage II and IIIa.
  • For postoperative adjuvant therapy, immunochemotherapy was most effective in patients with stage III.
  • Consequently, early detection and real curative resection with radical lymph node dissection, followed by immunochemotherapy (particularly in patients with stage III gastric cancer) should be recommended as a standard treatment principle for patients with gastric cancer.
  • [MeSH-major] Gastrectomy. Lymph Node Excision. Stomach Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10895156.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 14
  •  go-up   go-down


81. Fernández-Lobato B, Díaz-Carrasco MS, Pareja A, Marín M, Vila N, de la Rubia A: [Therapeutic use and profile of toxicity of the FOLFOX4 regimen]. Farm Hosp; 2009 Mar-Apr;33(2):89-95
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic use and profile of toxicity of the FOLFOX4 regimen].
  • [Transliterated title] Uso terapéutico y perfil de toxicidad del esquema FOLFOX4.
  • INTRODUCTION: Since the publication of the MOSAIC test results in 2004, the FOLFOX4 regimen has been established as an adjuvant treatment which is recommended in stage III colorectal cancer.
  • METHODS: Descriptive study of treatments with FOLFOX4 prescribed between April 2005 and March 2007.
  • The following data was collected: age, gender, diagnosis, stage of the illness (TNM classification) and adverse reactions, expressing severity according to Common Toxicity Criteria 2.0.
  • The diagnoses were: 28 colon cancer (4 stage II, 17 stage III, and 7 stage IV), 10 rectal cancer (1 stage II, 4 stage III, and 5 stage IV) and 1 stage IV gastric cancer.
  • ) When the study was completed, 9 patients continued active treatment with the regimen (average 6.8 cycles.
  • 14 patients stopped their treatment (an average of 8.1 cycles) due to toxicity in 10 cases, clinical progression in 3 cases and one patient died.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Leucovorin / adverse effects. Leucovorin / therapeutic use. Male. Middle Aged. Organoplatinum Compounds / adverse effects. Organoplatinum Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480796.001).
  • [ISSN] 1130-6343
  • [Journal-full-title] Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria
  • [ISO-abbreviation] Farm Hosp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


82. Tamura S, Miki H, Okada K, Yoshimura M, Uji K, Yoshida A, Suzuki R, Nakahira S, Egawa C, Nakata K, Okamura S, Sugimoto K, Takatsuka Y: [Pilot study of neo-adjuvant chemotherapy involving intraperitoneal administration of paclitaxel and oral S-1 for patients with T3 gastric cancer]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2024-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pilot study of neo-adjuvant chemotherapy involving intraperitoneal administration of paclitaxel and oral S-1 for patients with T3 gastric cancer].
  • The prognosis of patients with T3 gastric cancer is poor, even if a curative resection is performed.
  • Novel combination neo-adjuvant chemotherapy has been introduced for T3 gastric cancer patients.
  • They were diagnosed with gastric cancer with serosal invasion (T3) without P1 and CY1 by staging laparoscopy.
  • We selected a combined chemotherapy with both paclitaxel and S-1.
  • After one course of this therapy, surgery was performed.
  • After one course, four patients underwent a total gastrectomy and one distal gastrectomy.
  • The final histological stagings were included one stage IB, one stage II, one stage IIIA, one stage IIIB, and one stage IV.
  • Three patients died at 10, 11, and 16 months after the initial treatment, and two have survived for 64 and 62 months.
  • As the intraperitoneal administration of paclitaxel and oral S-1 was well-tolerated, further studies should be conducted involving T3 gastric cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Oxonic Acid / administration & dosage. Oxonic Acid / therapeutic use. Paclitaxel / administration & dosage. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / administration & dosage. Tegafur / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Drug Combinations. Humans. Injections, Intraperitoneal. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pilot Projects

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106511.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


83. Sasaki E, Maeda Y, Sasaki T: [Comparison the standard therapies of gastric cancer in Japan with those in the West]. Gan To Kagaku Ryoho; 2007 May;34(5):700-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison the standard therapies of gastric cancer in Japan with those in the West].
  • We compare Japanese practice guidelines for gastric cancer with those published from National Comprehensive Cancer Network (NCCN).
  • However, Japanese investigators show lower mortality rate (0.8%) of D2 dissection, so D2 dissection is referred as standard for stage II/III disease in Japan.
  • In chemotherapy, ECF or taxanes (e.g., DCF) is referred as a prior therapy in NCCN, but 5-FU contain regimen (e.g., FP, LV/5-FU, S-1, or S-1/CDDP) as a prior therapy in Japan.
  • From the results of ACTS-GC, we think that adjuvant chemotherapy is referred as standard in Japan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Europe. Fluorouracil / administration & dosage. Humans. Japan. Lymph Node Excision. Mitomycin / administration & dosage. Neoplasm Staging. Practice Guidelines as Topic / standards. Survival Rate. Tegafur / administration & dosage. United States. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496440.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 50SG953SK6 / Mitomycin; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


84. Kodera Y, Ishiyama A, Yoshikawa T, Kinoshita T, Ito S, Yokoyama H, Mochizuki Y, Ito H, Tsuburaya A, Sakamoto J, Nakao A, Chubu Clinical Cancer Group: A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer; 2010 Aug;13(3):197-203
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703).
  • BACKGROUND: The outcome of stage III gastric cancer patients treated by D2 dissection followed by adjuvant chemotherapy with S-1 remains unsatisfactory.
  • Moreover, some patients with a preoperative diagnosis of stage II/III turn out to be stage IV after surgical exploration, and a standard postoperative treatment for this population has not been established.
  • METHODS: A feasibility study of postoperative S-1/cisplatin (CDDP) was performed with patients who underwent gastrectomy for what turned out to be a stage IV gastric cancer.
  • Causes of treatment failure were failure to fulfill criteria for starting a new course within 5 weeks of the last administration of S-1 in 7, patient refusal in 6, disease recurrence/progression in 4, need to reduce dose by two levels in 4, and two successive skips of CDDP in 3 patients.
  • The median progression-free survival time of all patients was 363 days.
  • CONCLUSIONS: Although promising in the neoadjuvant and advanced/metastatic setting, S-1/CDDP is too toxic as a postgastrectomy treatment for Japanese patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Oxonic Acid / therapeutic use. Postoperative Care. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease Progression. Dose-Response Relationship, Drug. Drug Combinations. Feasibility Studies. Female. Gastrectomy. Humans. Japan. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2010 May;21(5):1001-5 [19875759.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):25-30 [11957041.001]
  • [Cites] Gastric Cancer. 2006;9(2):129-35 [16767369.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Gastric Cancer. 2004;7(2):104-9 [15224197.001]
  • [Cites] Gastric Cancer. 2008;11(4):192-3 [19132479.001]
  • [Cites] Gastric Cancer. 2006;9(2):51-66 [16767357.001]
  • [Cites] Am J Surg. 2004 Mar;187(3):440-5 [15006580.001]
  • [Cites] Gastric Cancer. 2007;10(2):129-34 [17577624.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3402-7 [16740764.001]
  • [Cites] Oncology. 2007;73(1-2):65-71 [18334851.001]
  • [Cites] Gastric Cancer. 2007;10(1):29-34 [17334715.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] Jpn J Clin Oncol. 2008 Jul;38(7):504-6 [18617536.001]
  • [Cites] Oncology. 2008;74(1-2):37-41 [18544958.001]
  • [Cites] Eur J Surg Oncol. 2009 Nov;35(11):1158-63 [19328643.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1488-97 [15939717.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):781-5 [16804723.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 20820990.001).
  • [ISSN] 1436-3305
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


85. Starling N, Okines A, Cunningham D, Allum W, Wotherspoon A, Benson M, Thompson J, Thomas J, Brown G, Riddell A, Stavridi F, Ashley S, Oates J, Chau I: A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer; 2009 Jun 2;100(11):1725-30
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
  • Preoperative cisplatin/fluorouracil is used for the treatment of localised oesophageal carcinoma.
  • This phase II study aimed to assess the efficacy and safety of administering preoperative epirubicin/cisplatin/capecitabine (ECX).
  • Patients with stage II or III oesophageal/gastro-oesophageal junctional adenocarcinoma from one institution received 4 cycles of ECX (epirubicin 50 mg m(-2) day 1, cisplatin 60 mg m(-2) day 1, capecitabine 625 mg m(-2) b.i.d. daily) followed by surgery.
  • The primary end point was the pathological complete response (pCR) rate based on a Simon two-stage design.
  • Thirteen out of 28 (46%) evaluable patients responded to chemotherapy by EUS (>or=30% reduction in maximal tumour thickness).
  • Although associated with a low pCR rate, survival with ECX was comparable with published studies suggesting that pCR may not correlate with satisfactory outcome from preoperative chemotherapy for localised oesophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Deoxycytidine / analogs & derivatives. Epirubicin / therapeutic use. Esophageal Neoplasms / drug therapy. Fluorouracil / analogs & derivatives. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capecitabine. Combined Modality Therapy. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Apr 15;88(8):1788-95 [10760753.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):338-56 [11260097.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3058-65 [11408502.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1223-9 [11953876.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):1996-2004 [11956258.001]
  • [Cites] Gastrointest Endosc. 2002 May;55(6):655-61 [11979246.001]
  • [Cites] Lancet. 2002 May 18;359(9319):1727-33 [12049861.001]
  • [Cites] Br J Surg. 2004 Feb;91(2):199-204 [14760668.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] N Engl J Med. 1996 Aug 15;335(7):462-7 [8672151.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):485-91 [9242759.001]
  • [Cites] N Engl J Med. 1998 Dec 31;339(27):1979-84 [9869669.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 17;91(6):497-8 [10088616.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):1976-83 [15928658.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4330-7 [15781882.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4483-9 [16002838.001]
  • [Cites] Radiology. 2005 Sep;236(3):841-51 [16118165.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):659-68 [16129366.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2365-72 [16245310.001]
  • [Cites] J Surg Oncol. 2005 Dec 1;92(3):151-9 [16299786.001]
  • [Cites] Cancer. 2006 May 15;106(10):2119-27 [16607651.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD001556 [16855972.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] Am J Surg. 2007 May;193(5):614-7; discussion 617 [17434367.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3719-25 [17704421.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1673-9 [17660494.001]
  • [Cites] Contemp Clin Trials. 2008 Jan;29(1):32-41 [17544337.001]
  • [Cites] BMC Med. 2004 Sep 24;2:35 [15447788.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1086-92 [18309943.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • (PMID = 19436301.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2695693
  •  go-up   go-down


86. Díez M, Medrano MJ, Gutierrez A, López A, Mugüerza JM, Hernández P, Lozano O, Noguerales F, Ruíz A, Granell J: P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy. Anticancer Res; 2000 Sep-Oct;20(5C):3929-33
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
  • BACKGROUND: The aim of the present study was to evaluate the influence of p53 protein on the survival of patients undergoing radical gastrectomy and postoperative adjuvant chemotherapy for gastric cancer.
  • PATIENTS AND METHODS: It was a retrospective study of 46 patients with gastric adenocarcinoma (Stage II and III of the Japanese staging system).
  • Alypatients were treated by curative radical gastrectomy with regional lymphadenectomy plus adjuvant chemotherapy.
  • Multivariate analysis performed on patients with Stage III tumors, separately, confirmed the predictive effect of p53 overexpression.
  • CONCLUSION: The results suggest that postoperative adjuvant chemotherapy acted differently in p53-positive than in p53-negative gastric tumors.
  • Absence of p53 overexpression is associated to longer survival when adjuvant therapy is administered.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / pathology. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Follow-Up Studies. Gastrectomy. Humans. Immunohistochemistry. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Mitomycin / administration & dosage. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Regression Analysis. Retrospective Studies. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11268479.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53; 50SG953SK6 / Mitomycin
  •  go-up   go-down


87. Wydmański J, Suwiński R, Miszczyk L, Maka B, Maciejewski B: [Evaluation of tolerance and efficacy of postoperative combined radiotherapy and chemotherapy in locally advanced gastric cancer]. Przegl Lek; 2005;62(12):1431-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of tolerance and efficacy of postoperative combined radiotherapy and chemotherapy in locally advanced gastric cancer].
  • PURPOSE: To assess the toxicity and the efficacy of adjuvant radio-chemotherapy in patients with high-risk gastric cancer.
  • METHODS AND MATERIALS: Patients with adenocarcinoma of the stomach were enrolled into the study from April 1999 to December 2000.
  • There were following inclusion criteria: tumor stages T1-2 N1-3 or T3-4 N0-3, no distant metastases (except resected metastases to sac or spleen).
  • Radiation dose of 42.5 Gy in 1.7 Gy per fraction was delivered to the tumor bed and regional lymph nodes over 5 weeks.
  • In 4 cases of nonradical surgery a boost dose of 8.5 Gy was given.
  • Chemotherapy consisted of 5-Fu 325 mg/m2/day, given on day 1-3 and 29-31 of radiotherapy.
  • Three year survival rates in stage II, III and IV were 67%, 24% and 17% respectively.
  • CONCLUSION: Postoperative radio-chemotherapy in patients with locally advanced gastric cancer was safe and well tolerated.
  • The results obtained in this study and from literature suggest that adjuvant radio-chemotherapy may improve 3-year survival rates by 10-15% compared to historical controls treated with surgery alone.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiography. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Preoperative Care / methods. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786766.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


88. Bouché O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, Baulieux J, Nordlinger B, Martin C, Seitz JF, Tigaud JM, Echinard E, Stremsdoerfer N, Milan C, Rougier P, Fédération Francophone de Cancérologie Digestive Group: Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol; 2005 Sep;16(9):1488-97
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801).
  • BACKGROUND: The aim of this study was to evaluate the efficacy of adjuvant chemotherapy after resection for gastric cancer in a randomized controlled trial.
  • PATIENTS AND METHODS: After curative resection, stage II-III-IVM0 gastric cancer patients were randomly assigned to postoperative chemotherapy or surgery alone.
  • At 97.8 months median follow-up, 5- and 7-year overall survival were 41.9% and 34.9% in the control group versus 46.6% and 44.6% in the chemotherapy group (P=0.22).
  • CONCLUSION: There was no statistically significant survival benefit with this toxic cisplatin-based adjuvant chemotherapy, but a risk reduction in recurrence was observed.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15939717.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


89. Wilke HJ, Van Cutsem E: Current treatments and future perspectives in colorectal and gastric cancer. Ann Oncol; 2003;14 Suppl 2:ii49-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatments and future perspectives in colorectal and gastric cancer.
  • Given the high rate of distant spread, effective systemic therapy is key to improving survival in patients with colorectal cancer (CRC).
  • A recent controlled trial suggests that overall time to progression is maximized and toxicity minimized when an irinotecan/5-FU/FA combination is used first-line, followed by an oxaliplatin/ 5-FU/FA combination on progression.
  • In the adjuvant setting, 5-FU/FA is the standard of care in stage III disease but of uncertain value in stage II patients.
  • Use of highly active chemotherapy in patients with unresectable disease (particularly liver metastases) achieves responses that allow a subset of patients to proceed to potentially curative surgery.
  • The emergence of novel agents targeted at processes such as tumor angiogenesis will complement cytotoxic chemotherapy, while improved understanding of tumor biology should enable agents to be selected according to the likely sensitivity of the disease in a particular patient.
  • In gastric cancer also, surgery remains the only potentially curative treatment.
  • The extent of dissection required is debated, as is the potential benefit of adjuvant chemoradiotherapy (indeed the degree of resection may interact with the effect of adjuvant treatment).
  • In untreated metastatic gastric cancer, median survival is 3-4 months.
  • This can be increased to around 10 months using chemotherapy.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12810459.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 60
  •  go-up   go-down


90. Baek SK, Kim SY, Lee JJ, Kim YW, Yoon HJ, Cho KS: Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. Cancer Res Treat; 2006 Feb;38(1):19-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer.
  • PURPOSE: It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)-DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer.
  • We investigated whether the ERCC1 expression was associated with survival for gastric cancer patients in an adjuvant setting.
  • MATERIALS AND METHODS: We retrospectively analyzed 44 patients who were diagnosed with stage II or higher disease after undergoing curative resection and they had also received cisplatin-based chemotherapy.
  • CONCLUSION: The overall survival in gastric cancer patients who received cisplatin-based adjuvant chemotherapy after a curative resection is higher in those patients showing the overexpression of the ERCC1 gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2005 Mar;127(3):978-83 [15764785.001]
  • [Cites] Am J Surg Pathol. 2004 Dec;28(12):1553-9 [15577673.001]
  • [Cites] Nature. 1965 Feb 13;205:698-9 [14287410.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):309-16 [9440758.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):130-7 [9103402.001]
  • [Cites] Carcinogenesis. 1993 Oct;14(10):2177-80 [8222071.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3237-40 [8324733.001]
  • [Cites] Cancer. 1974 May;33(5):1219-5 [4856724.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2594-601 [15173214.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):532-9 [14696117.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2286-91 [12114432.001]
  • [Cites] J Clin Oncol. 2001 Dec 1;19(23):4298-304 [11731512.001]
  • [Cites] Acta Oncol. 2001;40(2-3):309-26 [11441938.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):453-7 [11008208.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1059-64 [10533448.001]
  • (PMID = 19771254.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2741659
  • [Keywords] NOTNLM ; Adjuvant therapy / Cisplatin / ERCC1 / Stomach neoplasms / Survival
  •  go-up   go-down


91. Lordick F, Jäger D: Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. Gastrointest Cancer Res; 2008 Jul;2(4):187-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers.
  • A number of advances recently have been made in the chemotherapeutic treatment of gastroesophageal cancer.
  • Perioperative combination chemotherapy based on cisplatin and 5-fluorouracil (5-FU) improves the prognosis of patients with stage II and stage III disease.
  • Preoperative initiation of chemotherapy seems to be essential for achieving this result, according to studies performed in the West.
  • On the other hand, Japanese investigators demonstrated that postoperative administration of oral fluoropyrimidine prodrugs can substantially improve the prognosis of patients with curatively resected gastric cancer.
  • The addition of docetaxel to cisplatin and 5-FU has significantly improved response rate, time to progression, and overall survival in patients treated for advanced gastric cancer, as well as prolonging time to definitive worsening of global health status and Karnofsky performance status.
  • Further improvements in outcome may be achieved when even more active chemotherapy combinations including docetaxel are systematically implemented into the preoperative treatment of locally advanced gastroesophageal cancers.
  • It is hoped that targeting these pathways will further increase the efficacy of biochemotherapy of gastroesophageal cancer.
  • Evaluating early response to biochemotherapy using metabolic imaging is a novel approach that may allow for tailoring systemic therapy to individual tumor biology.
  • A deeper understanding of the relevant pathognomonic molecular patterns and signatures in individual tumors may facilitate faster drug development and permit more accurate selection of active therapies in the future.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Endoscopy. 2010 Jan;42(1):42-5 [19967633.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1150-6 [3498014.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1543-8 [14504056.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3217-23 [17664469.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):566-71 [10440683.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2574-6 [15795413.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1665-72 [16873435.001]
  • [Cites] Carcinogenesis. 2007 May;28(5):947-56 [17183068.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 18;99(8):601-7 [17440161.001]
  • [Cites] Br J Surg. 2007 Dec;94(12):1468-76 [17948223.001]
  • [Cites] Clin Cancer Res. 2007 Oct 1;13(19):5869-75 [17908981.001]
  • [Cites] Ann Oncol. 2008 Aug;19(8):1450-7 [18558665.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Apr;66(1):84-90 [18243012.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):273-8 [15668283.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):380-3 [7914428.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):54-9 [12506170.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2580-5 [17577037.001]
  • [Cites] J Clin Oncol. 1986 May;4(5):685-96 [3517242.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):299-307 [11886009.001]
  • [Cites] J Intern Med. 2006 Nov;260(5):484-7 [17040255.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1263-9 [7999410.001]
  • [Cites] Am J Clin Oncol. 1988 Aug;11(4):461-4 [3407626.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):735-41 [16915294.001]
  • [Cites] Radiology. 2006 May;239(2):472-80 [16543584.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1673-9 [17660494.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5A):3029-34 [15517912.001]
  • [Cites] Semin Oncol. 1983 Jun;10(2 Suppl 2):29-31 [6603023.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Cancer Invest. 2006 Jun-Jul;24(4):346-50 [16777685.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] J Clin Oncol. 2007 Nov 1;25(31):4865-7 [17971580.001]
  • [Cites] Am J Clin Oncol. 1998 Aug;21(4):416-9 [9708646.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S81-5 [15479484.001]
  • [Cites] Anticancer Drugs. 1998 Apr;9(4):307-10 [9635920.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):858-63 [8608475.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1612-9 [16575012.001]
  • [Cites] Lancet Oncol. 2007 Mar;8(3):226-34 [17329193.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7711-23 [15520175.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):827-31 [2016625.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1237-44 [15718321.001]
  • [Cites] Mod Pathol. 2004 May;17(5):579-87 [15073595.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):609-16 [7993836.001]
  • [Cites] Semin Oncol. 1991 Feb;18(1 Suppl 3):64-72 [2003229.001]
  • [Cites] Ann Oncol. 2008 Nov;19(11):1882-7 [18669868.001]
  • [Cites] J Gastrointest Surg. 2004 May-Jun;8(4):448-53 [15120370.001]
  • [Cites] Eur J Surg. 2002;168(11):597-608 [12699095.001]
  • [Cites] Gut. 2006 Oct;55(10):1497-511 [16966704.001]
  • [Cites] J Nucl Med. 2005 Dec;46(12):2029-34 [16330567.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3205-9 [17664467.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1386-93 [17555797.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2774-80 [15254045.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):808-16 [15492562.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1005-14 [17972143.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):260-3 [16473928.001]
  • [Cites] Cancer Gene Ther. 2001 May;8(5):342-51 [11477454.001]
  • [Cites] Gan To Kagaku Ryoho. 1994 Jun;21(7):1033-8 [8210254.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Ann Oncol. 1991 Nov-Dec;2(10):751-4 [1801881.001]
  • [Cites] Cancer. 2006 May 1;106(9):1908-16 [16568451.001]
  • [Cites] Gastric Cancer. 2005;8(4):249-52 [16328600.001]
  • [Cites] J Surg Oncol. 2004 Aug 1;87(2):95-104 [15282704.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4922-7 [17050876.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1310-7 [2671287.001]
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3290-2 [17932722.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1326-33 [15919686.001]
  • [Cites] Expert Opin Biol Ther. 2007 Mar;7(3):397-404 [17309331.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):69-79 [17896140.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1435-42 [18349393.001]
  • [Cites] Oncology (Williston Park). 2004 Dec;18(14 Suppl 14):22-5 [15685830.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3953-8 [16921048.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):164-70 [8558192.001]
  • [Cites] Ann Oncol. 1995 Feb;6(2):153-6 [7540418.001]
  • [Cites] Int J Cancer. 1996 Mar 28;66(1):48-54 [8608965.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):1996-2004 [11956258.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2122-8 [15942629.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):483-9 [16052530.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1925-32 [17680242.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5201-6 [17114652.001]
  • [Cites] Ann Surg Oncol. 2001 Jul;8(6):519-24 [11456051.001]
  • [Cites] Gastric Cancer. 2005;8(2):78-85 [15864714.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):33-40 [17133415.001]
  • [Cites] Cancer J Sci Am. 1998 Jul-Aug;4(4):269-74 [9689986.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7 [16857803.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3058-65 [11408502.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Semin Oncol. 1994 Aug;21(4 Suppl 7):58-66 [8091242.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4319-28 [15514373.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2544-8 [16735707.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):163-8 [9093725.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1344-7 [15319239.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):3051-7 [17505008.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3210-6 [17664468.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):510-7 [17164226.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1773-81 [15550582.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4603-9 [17925555.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3899-905 [17606723.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4528-35 [17925548.001]
  • (PMID = 19259285.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2632837
  •  go-up   go-down


92. Sato A, Nakamachi M: [Clinical development of chemotherapy for advanced gastric cancer]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1461-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical development of chemotherapy for advanced gastric cancer].
  • The ACTS-GC trial suggested that adjuvant chemotherapy with S-1 should be adopted as the standard treatment for stage II/III gastric cancer after curative D2 gastric dissection.
  • In the JCOG9912 trial (5-FU vs CPT-11+CDDP (CP), 5-FU and vs S-1), the MSTs were 9.0, 12.1, and 10.5 months for 5-FU, CP, and S-1, respectively, with S-1 demonstrating significant non-inferiority to 5-FU, while CP did not show statistically significant superiority to 5-FU.
  • In the SPIRITS trial comparing S-1 alone with S-1+CDDP, the MSTs were 11.0 and 12.0 months for S-1 and S-1+CDDP, respectively, and S-1+CDDP showed statistically significant superiority to S-1 monotherapy.
  • The GC0301/TOP-002 trial compared CPT-11+S-1(IRI-S)to S-1 alone in advanced gastric cancer patients.
  • On the basis of these results, S-1+CDDP was adopted as the standard cancer chemotherapy regimen for inoperable and recurrent gastric cancer in Japan.
  • Thus, in the next revision, the contents of the description of the Japanese Guidelines for Treatment of Gastric Cancer (2nd Edition) will be changed.
  • Now, the second-line treatment and the biological molecular targeting agents-based drug medicine treatment development are continued with an eye to the future.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799898.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


93. Sakuma K, Hosoya Y, Arai W, Haruta H, Ui T, Kurashina K, Saito S, Hirashima Y, Yokoyama T, Zuiki T, Hyodo M, Nagai H, Yasuda Y, Shirasaka T: Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity. Int J Clin Oncol; 2010 Apr;15(2):166-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity.
  • BACKGROUND: In patients with adverse events of S-1, the dose is generally reduced or the treatment cycle is shortened.
  • Whether the therapeutic effectiveness of modified regimens is similar to that of the standard dosage remains unclear.
  • METHODS: We retrospectively studied patients with gastric cancer who received S-1 on alternate days.
  • In 116 patients, S-1 was initially given at the standard dosage but was switched to alternate-day treatment because of toxicity within 28 days on average.
  • The other 150 patients initially received alternate-day treatment because of poor general condition.
  • In the adjuvant chemotherapy group (n = 96), the 3-year survival rate was 88% in patients with stage II, 73% in stage IIIA, and 67% in stage IIIB who underwent D2 lymph-node dissection.
  • In the palliative surgery group (n = 96), the response rate was 13%, with a median survival time (MST) of 624 days.
  • Among the 116 patients who initially received treatment on consecutive days, 100% had grade 1, 53% had grade 2, and 5.2% had grade 3 adverse events.
  • When S-1 was switched to alternate-day treatment, toxicity decreased in all patients.
  • In the 266 patients who received alternate-day treatment, 8% had grade 1, 6% had grade 2, and 0% had grade 3 adverse events.
  • CONCLUSION: Alternate-day treatment with S-1 may have milder adverse events without compromising therapeutic effectiveness.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Oxonic Acid / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Drug Combinations. Female. Gastrectomy. Humans. Kaplan-Meier Estimate. Lymph Node Excision. Male. Middle Aged. Palliative Care. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Clin Oncol. 2004 Jun;9(3):143-8 [15221596.001]
  • [Cites] Invest New Drugs. 2000 Nov;18(4):315-29 [11081568.001]
  • [Cites] Cancer. 1965 Oct;18(10):1189-213 [5890960.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Sep;29(9):1651-5 [12355955.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Int J Clin Oncol. 2008 Jun;13(3):196-200 [18553227.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Gastric Cancer. 2005;8(1):6-11 [15747168.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Int J Clin Oncol. 2008 Dec;13(6):483-7 [19093174.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Jpn J Clin Oncol. 2009 Jan;39(1):2-15 [19052037.001]
  • [Cites] Int J Clin Oncol. 2008 Dec;13(6):515-20 [19093179.001]
  • [Cites] Jpn J Clin Oncol. 2008 Jul;38(7):504-6 [18617536.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Feb;61(2):335-43 [17922276.001]
  • [Cites] Jpn J Clin Oncol. 2008 Dec;38(12 ):810-5 [18988666.001]
  • [Cites] Gastroenterology. 1963 Dec;45:721-9 [14134007.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Feb;31(2):237-40 [14997759.001]
  • (PMID = 20195683.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


94. Hasegawa H, Fujitani K, Kurokawa Y, Hirao M, Nakazuru S, Mita E, Tsujinaka T: Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer. Chemotherapy; 2010;56(6):436-43
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer.
  • BACKGROUND: As S-1 monotherapy has recently become the standard adjuvant regimen for stage II-III gastric cancer patients after curative gastrectomy in Japan, the question whether adjuvant S-1 affects the subsequent clinical course of relapsed patients has attracted great concern.
  • PATIENTS AND METHODS: We retrospectively evaluated the effect of adjuvant S-1 on survival following recurrence and efficacy of first-line treatment in patients with recurrent gastric cancer after curative gastrectomy.
  • Thirty patients received adjuvant S-1 (cohort A), 10 patients were given adjuvant chemotherapy with other oral 5-FU agents (cohort B) and 49 patients received no adjuvant chemotherapy (cohort C).
  • RESULTS: Median survival time following recurrence was 287 days in cohort A, 451 days in B and 547 days in C, with a significant difference between A and C (p = 0.0034).
  • Response rates of the first-line chemotherapy after recurrence were 6.7, 30.0 and 42.9% in cohorts A, B and C, respectively, with a significant difference between A and C (p = 0.0007).
  • On multivariate analysis, S-1 adjuvant chemotherapy was independently associated with poor prognosis after recurrence (hazard ratio 2.64).
  • CONCLUSION: S-1 adjuvant chemotherapy significantly reduced survival and response to first-line chemotherapy following recurrence in patients with recurrent gastric cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / therapeutic use. Gastrectomy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Combinations. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21088394.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; U3P01618RT / Fluorouracil
  •  go-up   go-down


95. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol; 2006 Aug 20;24(24):3953-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
  • PURPOSE: Preoperative therapy for localized gastric cancer has considerable appeal.
  • Combined-modality therapy quality, survival, and safety were secondary end points.
  • PATIENTS AND METHODS: Patients with localized gastric adenocarcinoma were eligible.
  • Patients received two cycles of induction fluorouracil, leucovorin, and cisplatin followed by concurrent radiation and chemotherapy (infusional fluorouracil and weekly paclitaxel).
  • Quality of therapy was assessed with other end points.
  • Forty-nine patients were entered and 43 were assessable (12% stage IB; 37% stage II; and 52% stage III).
  • Chemotherapy, radiotherapy, and surgery per protocol (including acceptable variations) occurred in 98%, 44%, and 63% of patients, respectively.
  • CONCLUSION: For localized gastric cancer, preoperative chemoradiotherapy strategy achieved a pathCR rate of more than 20% in a cooperative group setting.
  • With some refinements, this preoperative chemoradiotherapy strategy is poised for a randomized comparison with postoperative adjuvant chemoradiotherapy in patients with gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Neoadjuvant Therapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant / adverse effects. Disease-Free Survival. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant / adverse effects. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921048.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U10 CA37422
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


96. Wals A, Contreras J, Macías J, Fortes I, Rivas D, González P, Herruzo I: Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk. Clin Transl Oncol; 2006 Apr;8(4):271-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk.
  • OBJECTIVE: To calculate the Normal Tissue Complication Probabilities (NTCP) for the liver, right kidney, left kidney and spinal cord, as well as the global Uncomplicated Tumour Control Probability (UTCP) in gastric cancer patients who underwent a treatment with radiotherapy after radical surgery in our environment.
  • MATERIAL AND METHOD: In April 2000, a postoperative chemotherapy (QT-RT) protocol started in the province of Malaga for Gastric Adenocarcinomas with postsurgical stage II or higher (pT3-4 and/or pN+).
  • Differences between the 2 treatment techniques were analysed (2-field versus 4-field technique).
  • It is important to stress that the calculations of the TCP and NTCP have a limited quantitative signification but they are useful and beneficial in order to decide between treatment plans when they are supported by the clinical knowledge.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Algorithms. Kidney / radiation effects. Liver / radiation effects. Radiation Injuries / diagnosis. Radiotherapy, Adjuvant / adverse effects. Spinal Cord / radiation effects. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant / adverse effects. Computer Simulation. Dose-Response Relationship, Radiation. Female. Fluorouracil / administration & dosage. Gastrectomy. Humans. Imaging, Three-Dimensional. Leucovorin / administration & dosage. Male. Middle Aged. Organ Size. Organ Specificity. Radiotherapy Planning, Computer-Assisted. Retrospective Studies. Risk

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):137-46 [2032884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):283-93 [11872272.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):929-34 [9869212.001]
  • [Cites] Acta Oncol. 2001;40(2-3):309-26 [11441938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1623-30 [2722599.001]
  • [Cites] Radiat Res Suppl. 1985;8:S13-9 [3867079.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):439-47 [10760441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):123-35 [2032883.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):589-98 [10701738.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):983-93 [10705021.001]
  • (PMID = 16648103.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


97. Büyükçelik A, Onur H, Akbulut H, Bülent Y, Ensari A, Utkan G, Onal BS, Içli F: Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin. Tumori; 2005 Jul-Aug;91(4):302-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin.
  • AIMS AND BACKGROUND: We evaluated the prognostic value of p53 protein, DNA content and S-phase fraction in patients with adenocarcinoma of the stomach or the gastroesophageal junction treated with adjuvant etoposide, doxorubicin and cisplatin.
  • METHODS AND STUDY DESIGN: Thirty-five consecutive patients with stage II or III gastric or gastroesophageal junction adenocarcinoma treated with at least two cycles of adjuvant etoposide, doxorubicin and cisplatin after curative gastric resection were included.
  • P53 expression was detected in 42.9% (15 of 35) of gastric cancer tissues of the patients.
  • Also, p53-positive patients had a poor survival close to the level of significance (P = 0.051).
  • CONCLUSIONS: This trial supports the results of previous reports that p53 immunoreactivity is a prognostic factor for patients with adenocarcinoma of stomach or gastroesophageal junction treated with adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Flow Cytometry. Stomach Neoplasms / drug therapy. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Esophagogastric Junction. Etoposide / administration & dosage. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Ploidies. Predictive Value of Tests. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277093.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


98. Thong-Ngam D, Tangkijvanich P, Mahachai V, Kullavanijaya P: Current status of gastric cancer in Thai patients. J Med Assoc Thai; 2001 Apr;84(4):475-82
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of gastric cancer in Thai patients.
  • To determine the current status in various aspects of gastric cancer in Thai patients, we retrospectively reviewed the records of 119 patients with histologically proven gastric cancer in King Chulalongkorn Memorial Hospital during the five-year period from 1994 to 1998.
  • Lesion location was lower third in 40.3 per cent, middle third in 31.9 per cent, upper third in 15.1 per cent and entire stomach in 3.4 per cent of patients.
  • The TMN staging was as follows: stage II, 5.9 per cent; stage III, 9.2 per cent; and stage IV, 68.9 per cent. (the stage was unknown in 16%).
  • Management was surgical treatment in 58.9 per cent (total gastrectomy 14.5%, subtotal gastrectomy 33.3% and palliative bypass surgery in 11.1%).
  • Systemic chemotherapy was the primary modality of therapy in 16.8 per cent and was adjuvant therapy in 18.5 per cent.
  • The median survival time of resectable cases was 1.00+/-0.53 years, significantly longer than that of unresectable cases (0.11+/-0.03 years) (p=0.0025).
  • However, the administration of chemotherapy did not improve the survival rate.
  • It is concluded that, in Thailand, gastric cancer continues to be an important health problem and is generally associated with a poor prognosis.
  • [MeSH-major] Stomach Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11460956.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


99. Barone C, Cassano A, Pozzo C, D'Ugo D, Schinzari G, Persiani R, Basso M, Brunetti IM, Longo R, Picciocchi A: Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer. Oncology; 2004;67(1):48-53
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
  • OBJECTIVE: The prognosis in T3-T4 or N+ gastric cancer is dismal, and the role of adjuvant therapy remains uncertain.
  • Neoadjuvant chemotherapy could improve both resectability and survival.
  • Here, we report the results of the long-term follow-up of a pilot study aimed at evaluating a neoadjuvant treatment in a group of patients carefully staged by computed tomography (CT), endoscopic ultrasound and laparoscopy.
  • METHODS: Twenty-five stage II-III patients with histologically proven gastric adenocarcinoma were enrolled in the study.
  • Three further cycles of chemotherapy were planned after radical surgery.
  • RESULTS: Twenty-four patients received the planned pre-operative chemotherapy and underwent surgical resection; total (13 patients) or subtotal (7 patients) R0 D2 gastrectomy was possible in 20 patients.
  • One patient died as a result of gastric bleeding.
  • The main toxicity was grade 3/4 neutropenia (68%), which occurred more frequently during the postoperative chemotherapy, and fatigue (68%).
  • CONCLUSION: The notable long-term survival in the present study suggests a comparison between the neoadjuvant approach, including new drug combinations, and adjuvant chemo- or chemoradio-therapy in locally advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Epirubicin / analogs & derivatives. Neoadjuvant Therapy / methods. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Follow-Up Studies. Glucuronates / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 15459495.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Glucuronates; 0 / epidoxorubicin glucuronide; 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


100. Jeung HC, Rha SY, Noh SH, Min JS, Kim BS, Chung HC: Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. Cancer; 2001 Jun 1;91(11):2016-25
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute.
  • BACKGROUND: The authors evaluated the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) plus doxorubicin in gastric carcinoma after D2-3 curative resection.
  • METHODS: A total of 301 patients with Stage II to IV (en bloc resected T4b; 1984 American Joint Committee on Cancer staging) were accrued between 1984 and 1996.
  • Chemotherapy was started within 4 weeks of surgery according to the following schedule: intravenous bolus injection of doxorubicin 40 mg/m2 every 3 weeks for 12 cycles and 5-FU 400 mg/m2 weekly for 60 weeks.
  • Sixty-four percent of the total patients and 71.7% of the patients who did not experience recurrence during the chemotherapy finished the protocol completely with acceptable toxicities.
  • Treatment completion group showed survival benefit over the early termination group in 5-year survival (75.2% vs. 52.9%; P = 0.0005).
  • Multivariate analysis demonstrated that completion of chemotherapy is an independent prognostic factor of both disease free and overall survival.
  • CONCLUSIONS: Adjuvant chemotherapy with 5-FU plus doxorubicin for 60 weeks after D2-3 dissection induced promising survival duration with acceptable toxicities.
  • Full administration of the planned dosage of the combined drugs is recommendable as opposed to early termination of the chemotherapy in gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Doxorubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Injections, Intravenous. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11391580.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement